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ABSTRACT
PATIENT ACTIVATION AND MEDICATION ADHERENCE AFTER
PHARMACOGENETIC CARE IN A CARE COORDINATION POPULATION
JULIE KITTELSRUD
2016
Objective. The purpose of the study is to compare the outcomes of patient activation
before and after pharmacogenetic care in a coordinated care population. The process of
pharmacogenetic care includes the patient’s acknowledgment of medication changes
which are based on their genetic profile. This study will be framed by Dorothea Orem’s
Self-Care Theory and Davies and Conley’s framework of genetic influences in
prescribing anti psychotropic therapy.
Background. Understanding patient’s behavioral reactions to pharmacogenetic care in
terms of patient activation is important to understanding patient’s health outcomes. No
published studies were identified in literature reviews conducted by this author which
related to patient activation and pharmacogenetic care. There were no published studies
found by the author using either, or both of, Dorothea Orem’s Self-Care Theory or
Davies and Conley’s framework.
Methods. This dissertation study is designed as part of a larger study nicknamed “PGXTIME”. The study is a longitudinal, utilizing one-group, repeated measure design.
Participants will complete the Patient Activation Measure-Mental health (PAM-MH)
before and after having pharmacogenetic testing (PGX). Medication recommendations
will be provided to the primary care provider based on current medications and genetic
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testing results. Standard of care in South Dakota requires patient involvement and
communications regarding genetic testing. This study requires a patient’s
acknowledgment that their medications are remaining the same or being modified based
on pharmacogenetic testing results. Additional information will be collected regarding
the number of chronic conditions, the number of mental health conditions, the number of
medications utilized, coordinated care tier level and number of genetic pathways
affected. A theoretical model was developed based on literature review, Orem’s model,
Davies and Conley’s framework, to understand direct and indirect variable relationships.
Results. This study was stopped in January of 2016. Therefore, no study results are
presented in this dissertation. Chapter one and two describe this study while chapter
three describes the reason the study was stopped and how the study changed. Chapter
four presents study results, and Chapter Five includes the discussion.
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CHAPTER 1
Introduction
Phenomenon of Interest
Mental illness is a common and significant co-morbid condition to other healthrelated problems such as diabetes (Trief et al., 2014), cardiovascular disease (Sin, Yaffe,
& Whooley, 2015), and obesity (Stanley, Laugharne, Addis, & Sherwood, 2013). The
combination of chronic disease associated with mental health diagnoses cost the U.S.
healthcare system over $300 billion dollars in 2002, and about $210 billion of this is
related to work absenteeism costs due to worker impairment. Reeves et. al. (2011)
found that in South Dakota approximately three days per month are used for mental
health days indicating loss of work time (Reeves et al., 2011). Many studies have
evaluated the best way to care for patients with depression through primary care and
psychiatric care including a more recent large-scale study titled the Sequenced
Treatment Alternatives to Relieve Depression (Ben-Zeev et al., 2012; Smith, Easter,
Pollock, Pope, & Wisdom, 2013; Steigman et al., 2014; Tosh, Clifton, Xia, & White,
2014; Wisniewski et al., 2004)
Patient activation is one’s knowledge, skills and ability to navigate the health
care system (Hibbard, Sockard, Mahoney, & Tusler, 2004). Patient activation is also
closely related to health outcomes in persons with chronic illness and mental health
diagnoses, and authors report that those who have higher activation levels have
improved mental health outcomes even a year later (Sacks, Greene, Hibbard, & Overton,
2014). Another measure of patient activation is medication adherence (Hibbard, et al.,
2004).

2
Evidence has demonstrated that medication adherence in chronic mental illness
is poor and that medication non-adherence increases the incidence of re-hospitalization
along with worsening patient outcomes (Mosen et al., 2007; Remmers et al., 2009).
Medication management of mental illness most often includes more than one medication
over long periods of time (Blaschke, Osterberg, Vrijens, & Urquhart, 2012). A German
study by Stieffenhofer and Hiemke (2010) indicated that medication side effects, which
occur because of personal enzymatic pathways associated with one’s genetic make-up,
may play a role in discontinuation of medications. Hall-Flavin et al. (2013) note that
pharmacogenetic guidance in medication selection reduced symptoms and improved
clinical outcomes for patients. Pharmacogenomics (PGX) is the study of genetics as
they relate to the cytochrome P450 (CYP) enzymatic metabolism of medications in the
liver (Zhou, Liu, & Chowbay, 2009). Pharmacogenetic testing in recent years has been
reported to decrease side effects which may contribute to reducing medication nonadherence (Hall-Flavin et al., 2013; Mrazek, 2010b). Currently, there are no identified
published studies that evaluate the effect pharmacogenetic testing has on patient
activation, and one published study related to medication adherence (Fagerness et al.,
2014). There is a growing body of evidence regarding improvement of patient outcomes
related to positive changes in patient activation (Sacks, et al., 2014; Sacks, Greene,
Hibbard, Overton, 2014)(R. M. Sacks, J. Greene, J. H. Hibbard, & V. Overton, 2014).
Additionally, studies address the potential of pharmacogenetic testing to impact
medication adherence because of the reduction of side effects (Hall-Flavin et al., 2013;
Hall-Flavin et al., 2012). It is the intent of this study to evaluate patient activation
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before and after pharmacogenetic testing has been performed to confirm or adjust patient
medications.
Background
Few published research studies have focused on the effect genetic testing, such as
pharmacogenetic testing, has on patient behavior (Sacks et al., 2014; Sacks et al, 2014)
patient behavior. The process of conducting genetic testing requires a specific process be
followed in South Dakota, and standard of care requires open communications between
providers and patients. As the standard of care, the provider will discuss the testing and
any medication changes based on the pharmacogenetic testing results with the patient's
acknowledgment of the process (Appendix A). This process will be considered
pharmacogenetic care for this study.
There are currently no published studies identified at this time, which examine
patient activation and pharmacogenetic care. Patient activation improves not only
medication adherence but also health outcomes. When a patient is activated or engaged
in their healthcare, there is increased motivation in health-related behaviors. Some of
these include; improved diet, exercise and obtaining preventative screening tests
(Hibbard et al., 2004). Several studies have reported that high patient activation
measures correlate to better health outcomes in biometric indicators of health such as
blood pressures, Hemoglobin A1C (HgA1C) levels, cholesterol levels, and body mass
index (Hibbard & Greene, 2013; Rogvi, Tapager, Almdal, Schiotz, & Willaing, 2012; R.
Sacks et al., 2014; Skolasky, Mackenzie, Wegener, & Riley, 2011).
A component of the measurement of patient activation is the outcome of
medication adherence. Haga and LaPointe (2013) have speculated that the act of

4
pharmacogenetic testing will increase a patient’s medication adherence. However, only
one published study was identified by Fagerness et al. (2014) which examined pharmacy
refill data for those patients who received pharmacogenetic testing. This study reported
higher medication adherence in those patients who had genetic testing over those who did
not have testing. Furthermore, Haga and LaPointe (2013) described additional factors
that may relate to other positive impacts of pharmacogenetic testing, such as less need for
medication dosing adjustments, fewer changes in medications, fewer side effects,
opening communication between provider, and patient and the potential of less time to
therapeutic outcomes. These factors may contribute to medication adherence after
pharmacogenetic testing and, therefore, increase patient activation.
Some studies have addressed improved medication adherence in patients who
have had genetic risk testing (Charland et al., 2014; Grant et al., 2009). Grant et al.
(2009) reported that participants with and without type 2 diabetes indicated in a selfreport survey that they would be more likely to have higher motivation to change their
lifestyle if they had a ‘high risk’ gene for diabetes. Moreover, participants described that
they would be ‘much more motivated’ to be compliant with their medications (Grant et
al., 2009). Additionally, Charland et al. (2014) reports increased adherence to statin
medications after testing the risk gene, KIF6, which indicates increased risk for
Congestive Heart Disease (CHD). One recent study evaluating retrospective health
claims refill data, noted that those participants who had pharmacogenetic testing were
more adherent to their medication (Fagerness et al., 2014).
Patient activation has been noted to be low in patients with mental health
disorders (Gunn et al., 2012; R. Sacks et al., 2014; Whooley et al., 2008). As defined by
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Hibbard (2008) activation refers to how engaged one is in managing his or her healthcare
and this can change over time. It follows that if pharmacogenetics may improve a
patient’s engagement in their healthcare, medication adherence may also improve. The
amount of activation a patient may have in his or her healthcare is variable based on
patient interest, skills, the capacity to understand and diagnoses (Von Korff, Gruman,
Schaefer, Curry, & Wagner, 1997). To date, there were no studies identified in this
author’s literature review which examined the patient response to pharmacogenetic
testing as a relationship to patient activation.
Problem statement
Pharmacogenetics is an innovation that is becoming more widely accepted as a
clinical application of genetics, and its implementation has shown benefit with
psychiatric medications in mental health (Hall-Flavin et al., 2013; Mrazek, 2010a;
Mrazek & Lerman, 2011). Within the context of clinical implementation,
pharmacogenetic (PGX) testing may have indirect effects that may benefit patient
behavior, such as increasing medication adherence (Charland et al., 2014). It follows
that if there is evidence of increasing medication adherence, there could also be an
increase in patient activation. However, a study utilizing patient activation has not been
conducted in mental health and chronic illness population in association with medication
adjustments based on pharmacogenetic testing.
Purpose of the Study
The purpose of the study was to compare the outcome of patient activation
before and after medication recommendations have been made utilizing
pharmacogenetic testing information in a chronic illness and mental health population.
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Care coordination patients had access to pharmacogenetic care. Based on
pharmacogenetic testing and a pharmacist’s review of current medications,
recommendations for medication and or dosage adjustments were made. The provider
was assigned to oversee the patient along with the care coordinator who provided the
information to the patient regarding their completed pharmacogenomic testing results.
Also, the coordinator and or the provider communicated that their medications were
being adjusted based on the genetic test. The patient acknowledged that their
medication is being changed or not changed based their personal genetic profile. Other
variables that were collected for a primary study (PGX-TIME) were also incorporated
into the analysis for the dissertation such as, demographic information, number of CYP
enzyme pathways that are clinically affected by decreased or increased enzyme activity,
number of chronic conditions, the number of prescription medications and the number of
mental health conditions.
Research Questions and Hypotheses
1. Does patient activation improve from admission to one month of care
coordination in a population of patients with chronic conditions and mental
illness?
a. Patients with chronic conditions and mental health will improve patient
activation scores after beginning care coordination.
b. H0 = PAT1 = PAT2
c. H1 = PAT1 < PAT2
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2. Does patient activation improve after pharmacogenetic care in patients with
chronic illness and mental health diagnoses who are participating in a care
coordination population?
a. Patient activation scores will improve from time 2 to time 3 after
pharmacogenetic care.
b. H0 = PAT2 = PAT3
c.

H1 = PAt2 < PAt3

3. Does patient activation improve after patients with chronic illness and mental
health enter care coordination and have pharmacogenetic care?
a. Patient activation scores will improve from time 1 to time 3 after entry to
care coordination and pharmacogenetic care.
b. H0 = PAT1 = PAT3
c.

H1 = PAT1 < PAT3

4. Do the classifications of TIER level, number of medications, number of
chronic illnesses, and number of affected genes, affect the level of change in
patient activation in a care coordination population?
Nursing Theory
Dorothea Orem’s Theory of Self-Care Deficit includes three midrange theories,
which together attempt to define nursing practice and guide nursing curriculum (Orem,
2001). The three theories include; Theory of Self-Care, Theory of Self-Care Deficit, and
Theory of Nursing Systems (Orem, 2001; Parker & Smith, 2010). This study will
incorporate the Theory of Self-Care as measured by the PAM-MH and MMAS-8.
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Three central concepts including; “self-care, self-care agency and therapeutic
self-care demand” make up self-care theory (Denyes, Orem, & Bekel, 2001; Nursing
Development Conference Group, 1979; Orem, 1987, p. 70) Self-Care is a learned,
voluntary and deliberate activity to maintain wellness and health (Nursing Development
Conference Group, 1979; Orem, Taylor, & Renpenning, 1995). Patient activation
(PAM-MH) is evidence of self-care in its measures of self-capability, learned knowledge
and beliefs of health care and medication use (Green et al., 2010; Hibbard et al., 2004).
Additionally, medication adherence, as measured by the MMAS-8, is evidence of selfcare and self-care requisites (Morisky, Ang, Krousel-Wood, & Ward, 2008).
Self-care agency is the power and ability to care for the self, and, therefore,
nursing agency is the capability, knowledge and insight into the patients needs as selfcare agents with deficits (Renpenning & Taylor, 2003). Motivation and motives are the
basis for self-care agency and are followed by the health behavior actions. This study
evaluated self-care agency as a component of patient activation, and medication
adherence as a part of self-care requisites.
Theoretical Framework
Davies, Conley and Puskar (2010) produced a theoretical framework targeted to
the practicing clinician. It was developed by evaluating challenges that clinicians face
when choosing antipsychotic medications. The challenges are that a provider must be
aware of, and knowledgeable regarding pharmacology of drugs, molecular genetics of
drug targets, and genetics of drug metabolism to prescribe medications (Davies, Conley,
& Puskar, 2010). Components of the framework related to patients include; family and
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patient education, medication planning, medication monitoring, and patient outcomes
(Davies et al., 2010).
Definition of terms
Mental health. Mental health conditions most commonly seen by the care
coordination team includes, depression, anxiety, personality disorders, post-traumaticstress disorder, bipolar-disease, and schizophrenia. However, this list may vary based
on the population of the primary study, PGX-TIME.
Serious Mental Illness (SMI). SMI is when mental health disorders are serious
enough to impact a patient’s activities of daily living (NIMH, 2012). The population for
this study has mental health conditions in the category of serious mental illness.
Patient Activation. An activated patient is a patient who has the knowledge,
skills and ability to navigate the health care system to engage in personal self-care to
maintain health and wellbeing (Hibbard et al., 2004).
Medication Adherence. Medication adherence is the ability and willingness to
take medications as they are prescribed by a provider on a continuing basis to maintain
health (Morisky et al., 2008; Morisky & DiMatteo, 2011).
Pharmacogenetics. Pharmacogenetics (PGX) is the study of genetics as they
are related to the cytochrome P450 (CYP) enzymatic metabolism of medications,
transporter and receptor genes in the liver (Zhou et al., 2009).
Pharmacogenetic care. Pharmacogenetic care refers to the provider and patient
interaction that surrounds the process of testing. These elements include the patient’s
informed consent to perform the genetic testing, a provider order, a return of genetic
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report with information regarding pharmacist recommendations and the patient’s
acknowledgment that medication changes were made based on their genetic profile.
Significance of the Study
This study is significant to patient outcomes, providers, and health systems.
Patients who have pharmacogenetic testing and show an improvement in patient
activation will have better health outcomes such as improved mental health conditions,
decreased depression, decreases in symptoms and side effects and overall, improved
quality of life. Potentially, there may be a benefit to both the patient and insurance
providers related to costs. For example, when one is started on the correct medication
because the provider understands not only the clinical picture but also the genetic
snapshot of a patient’s drug metabolism, the patient will have improvement in their
health conditions. Moreover, the patient may experience fewer side effects without the
expense of frequent changes in medications or additional medications to control these
side effects.
In consideration of providers and other professions working with patients,
opening communication between the provider and patient because of pharmacogenetic
testing may increase patient activation and medication adherence. Furthermore, increases
in activation and medication adherence may decrease the number of suicides, promote
patient’s active participation in preventative medicine, decrease missed clinic visits and
promote the intentional and appropriate use of resources. This study is a broad-reaching
study when considering the potential impact on patient’s health outcomes, costs to the
patient and hospital systems, and availability of new prescribing resources for the
provider in an ever-changing and complex system of pharmaceuticals.
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CHAPTER 2
Literature review
Introduction
Chapter two reviews the current literature as it relates to the primary points of
interest to this study. This study compared the outcome of patient activation before and
after medication recommendations had been made utilizing pharmacogenetic testing in a
chronic illness and mental health population. Therefore, current literature related to the
following topics was critically evaluated; (a) prevalence and trends in mental health care;
(b) patient activation, the concept itself and its relationship to chronic illness, diabetes,
hypertension, and mental health; (c) medication adherence; (d) pharmacogenetics and
behavioral outcomes; and (e) gaps in the literature related to pharmacogenetics and
behavioral outcomes in the mental health population.
Prevalence and Trends in Mental Health
Serious mental illness (SMI) as defined by the National Institute of Mental Health
(NIMH), as a diagnosis of mental illness in the 4th edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) seriously impacts a patient’s daily life
(NIMH, 2012). SMI accounts for 9.4 million people in the United States (US) alone,
which is about 4.1 percent of the US population (NIMH, 2012). The gender most
affected with SMI are females (4.9 %), and the age ranges between 26-49 years old
(5.2%) (NIMH, 2012). Also, Medicaid use within this population is significant at about
8.5% of patients with SMI (NIMH, 2012). Many patients with SMI do not seek out
mental health services. However, a survey in 2008 reports that 40% of patients with
mental health conditions first utilize primary care (Center for Disease Control, 2008).

12
Significant physical conditions are associated with mental illness and include diabetes
(Trief et al., 2014), cardiovascular disease (Sin et al., 2015), and obesity (Stanley et al.,
2013). The combination of mental illness and chronic conditions affect the ability of
patients to care for themselves. Additionally, poor outcomes, such as increased
depression, and increased suicide are associated with this combination of disorders
(Salyers, Matthias, Sidenbender, & Green, 2013; Trief et al., 2014).
There are many issues leading to under-recognition and insufficient treatment of
psychiatric illness in the primary care setting (Eisenberg, 1992; Gallo & Coyne, 2000;
Williams, 1998). One such issue is a general reluctance due to stigma, of patients to
report mental illnesses and instead, patients seek primary care services for somatic
complaints (Wells et al., 2000; Williams, 1998). The ability to seek appropriate care, as
part of patient activation, is an important step in self-care management (Chen, Mortensen,
& Bloodworth, 2014; Orem, 2001). Katon et al. (1997) estimate that as high as 80% of
patients with depression seek out primary care services for somatic complaints without
mention of depressive symptoms to the primary provider. Another issue is finding the
correct treatment for the patient. In the 1990’s the Food and Drug Administration (FDA)
approved Selective Serotonin Receptor Inhibitors (SSRI’s), which increased the number
of prescriptions through primary care services. This increase was related to the decreased
risk of side effects and the decreased need for follow-up (Cutler, 2001; Cutler &
McClellan, 2001).
Paton, Esop, Young, and Taylor (2004) conducted a clinic review of recorded
lipids and Body Mass Index (BMI) in schizophrenic patient charts, and reported that
these data were not found in the majority of schizophrenic patient charts reviewed.
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Similarly, Roberts, Roalfe, Wilson, and Lester (2007) examined charts of schizophrenia
patients who use primary care and found that an inequality of care exists compared to
other patients reporting that schizophrenia patients were half as likely to have blood
pressure and cholesterol levels checked than asthma patients. However, Tosh et al.
(2014) completed an extensive review of the literature and revealed that overall the
literature does not report clear inequalities between schizophrenia patients and other
patients. There is inconclusive, yet potentially negative evidence, in the literature review
regarding the quality of care, and access to care that patients with mental health
conditions experience.
Muir-Cochran (2006) report that patients with mental health conditions have
increased challenges with negotiating the medical system and therefore, are less activated
in their health care. It is documented that patients with mental illness are less engaged in
their health care than those without mental illness (Muir-Cochrane, 2006). Overall, the
high prevalence of complicated patients with mental health disorders who are being cared
for in primary practice illustrates a clear picture of the unmet needs of this population.
Patient Activation Literature Review
The literature was searched using the keyword in quotations, “patient activation”,
which yielded 944 articles on EBSCOhost choosing all databases. Limiting the scope to
the full article, and peer-reviewed articles, a total of 342 articles were available. When
the scope was narrowed to “patient activation” and “chronic illness”, 144 articles were
noted as available. These abstracts were reviewed for relevance to the study. Articles
were also obtained from the PAM website www.insigniahealth.com to total 71 articles
evaluating patient activation in various chronic disease states. A discussion of the
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concept development related to patient activation and a review of literature related to
chronic conditions follows.
Patient Activation
The socially driven underpinnings of the concept of “patient activation” are
directed at two main health initiatives. The first is the transition of reimbursement
towards patient-centered containment of costs with improving health outcomes or
consumer-driven insurance plans (Hibbard et al., 2004). The second is Bodenheimer,
Lorig, Holman, and Grumbach (2002) development of the Chronic Illness Care Model
(Hibbard et al., 2004).
Health plan impact. Consumer-driven health plans (CDHP) was a cutting-edge
topic debated at the 6th Annual World Health Care Congress in 2009 ("Making the Shift
to Consumer-Directed Health Care Remains a Challenge for Many," 2009). At the heart
of the discussions were issues related to empowerment of the patient to become engaged
in their health plan by allowing incentives from insurance companies ("Making the Shift
to Consumer-Directed Health Care Remains a Challenge for Many," 2009). The term
“consumer-driven” is a reference to the design of insurance reimbursement programs that
puts the patient at the center of the decision process for their personal care (Gabel, Lo
Sasso, & Rice, 2002, p. W395).
A study conducted by Loeppke et al. (2008) evaluated a health enhancement
program following a risk assessment on employees’ health. The health enhancement
program encouraged participants to make healthy choices and participants were able to
earn $300 off of their insurance premiums. The next year of health screenings showed an
improvement in health outcomes (Loeppke et al., 2008). Similarly, HRA plan members,
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who engaged in better health practices reportedly used less asthma, cardiac, and
cholesterol medications (Song, Levin, & Gartner, 2010). Wilson et al. (2008) researched
utilization differences between those enrolled in a CDHP and a comprehensive major
medical (CMM) plan. The findings show no differences in utilization of services in the
areas that were beyond the patient’s control such as inpatient hospital stays. However,
there was a significant reduction in the use of preventative services and emergency room
visits for those with CDHP’s (Wilson et al., 2008). An evaluation of CDHP members
reported that they followed healthier self-care behaviors than non-memebers. For
example, fewer members engaged in smoking, more members exercised, and more
obtained preventative exams (Fronstin, 2012). This example illustrates that a high
engagement in one’s self-care behaviors reportedly improves health outcomes.
Chronic illness care model impact. Edward H Wagner, MD developed the
Chronic Illness Care Model (CICM) which is based on six elements that when
incorporated by the patient and primary provider increase the collaboration and
effectiveness of the healthcare system (Bodenheimer, Wagner, & Grumbach, 2002).
These six pillars are similar to the philosophical underpinnings of patient activation and
include; support of self-management, clinical information structure, redesign of the
delivery system, decisional support, health care organization, and community resources
(Bodenheimer, Wagner, et al., 2002).
Philosophical underpinnings of Patient Activation. Hibbard et al. (2004)
conducted focus groups to understand and conceptualize “activation” and conducted a
literature review, searching terms related to the concept. This review identified six
domains which were utilized in focus groups and include; (a) self-management of
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symptoms; (b) engagement in health maintenance activities; (c) conduct activities that
maintain health; (d) participation in treatment decisions; (e) work with caregivers and
providers; (f) understand the health system operations and ability to navigate the system
(Hibbard et al., 2004). These six findings directed the focus group discussions.
An expert panel and patient panel were queried regarding patient’s “knowledge,
beliefs, and skill needed to manage and live with a chronic condition” as they relate to
each of the six identified areas found in the literature (Hibbard et al., 2004, p. 1008). The
expert panel identified that the patient is important in the areas of self-management,
collaborating with the provider, and maintaining function. Additionally, they concluded
that knowledge and skills are needed to self-manage, and maintain functional health.
Alternatively, they described that knowledge was not needed for collaboration with a
provider, but skills were valuable in collaborating with a provider (Hibbard et al., 2004).
Overall, activated patients believe in, and know how to, self-manage their chronic
conditions use their collaborative skills and have the ability to navigate the system.
Patient activation and disease states. Five studies identified, have provided
evidence that highly activated patients have better health behaviors such as, being
exercisers, non-smokers, and those who follow-up with preventative exams (Hibbard,
Mahoney, Stockard, & Tusler, 2005; Hibbard et al., 2004; Hibbard, Mahoney, Stock, &
Tusler, 2007). Overall, patient activation has been evaluated in many settings, and health
states representing chronic illness (Alexander, Hearld, Mittler, & Harvey, 2012; Kinney,
Lemon, Person, Pagoto, & Saczynski, 2015), diabetes (Begum, Donald, Ozolins, &
Dower, 2011; Rask et al., 2009; Woodard, Landrum, Amspoker, Ramsey, & Naik, 2014),
hypertension (Ryvicker, Feldman, Chiu, & Gerber, 2013; Thiboutot et al., 2013),
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orthopedic surgery (Skolasky, Mackenzie, Wegener, & Riley, 2008), heart failure
(Gardetto, 2014; Shively et al., 2013), Inflammatory bowel disease (Munson, Wallston,
Dittus, Speroff, & Roumie, 2009), and multiple sclerosis (Goodworth et al., 2014; Packer
et al., 2015; Stepleman et al., 2010).
Patient activation and chronic illness. Provider contact and communication
contributes to higher activation levels and is exemplified by the information that patients
with higher activation levels perceive a good relationship with their providers and see
that their treatment plans were fairly executed (Alexander et al., 2012). Additionally,
Wong, Peterson, and Black (2011) found that the more time spent with a provider, the
higher the activation level became. Overall, diabetic and cardiovascular disease patients
with higher activation decreased the number of visits to their provider, potentially
indicating better self-management (Donald et al., 2011).
Information on patient activation and patient outcomes are new and rapidly
growing with 27 articles published since 2007 relating to patient outcomes as they relate
to patient activation levels. It is important to understand how having a high, or low
activation level relates to patient outcomes. For example, those with low activation
levels were found to have a higher risk for re-hospitalization and risk for higher numbers
of emergency room visits (Kinney et al., 2015). When Remmers et al. (2009) conducted
a secondary analysis on data collected for a previous study by Mosen et al. (2007) and
collected additional information for each participant, they found that patient activation is
a malleable trait that declines over time. These authors suggested that this change is due
to a decreases in perceived health, and a reduction in ability to care for themselves
(Remmers et al., 2009). When health outcomes were assessed in the four areas of
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prevention, unhealthy behaviors, clinical indicators and costly utilization, it was found
that those with high activation had fewer emergency room visits and lower systolic blood
pressure. However when comparing those with high activation to those with lower
activation levels, triglycerides, Low-Density Lipoprotein (LDL), HgA1C levels and
diastolic blood pressures did not differ (Greene & Hibbard, 2012). Also, patients who
have low patient activation along with multiple chronic illnesses who participate in care
coordination tended to self-report problems with care coordination (Maeng, Martsolf,
Scanlon, & Christianson, 2012).
Patient activation and diabetes. Chronic conditions like diabetes require daily
monitoring plus the skill and knowledge to self-manage (Rask et al., 2009; Remmers et
al., 2009). Patient activation on the topic of diabetes care evaluated the health outcomes
of self-management, and associations with HgA1C. Rask et al. (2009) studied 287
African Americans, who were primarily female and uninsured, finding that those more
activated patients performed frequent foot exams, had eye exams annually, and higher
self-management skills. However, there was no evidence that patient activation had any
relationship to HgA1C levels (Rask et al., 2009). On the other hand, Remmers et al.
(2009) reflected that those who had higher PAM levels had lower HgA1C levels and
decreased LDL levels. Moreover, the converse was true as well, indicating a predictive
nature of the PAM to health outcome measures of HgA1C (Rask et al., 2009). In
contrast, Mayberry et al. (2010) concluded that only those with the highest level of
activation as scored by the PAM would see a decrease in HgA1C levels. These studies
indicate that patient activation has an impact on diabetes self-care, but that there may be
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other issues influencing HgA1C levels that are more complex than what patient activation
may measure.
Intervention studies have indicated that there are several methods to improve
activation and, therefore, diabetes self-care behaviors and outcomes. Bolen et al. (2014)
reviewed the literature and conducted a meta-analysis illustrating the effectiveness
though mild, of patient activation interventions. Social support and participatory decision
making as interventions were positively related to higher patient activation scores on the
PAM and better HgA1C levels (Parchman, Zeber, & Palmer, 2010; Schiotz, Bogelund,
Almdal, Jensen, & Willaing, 2012). It has been previously shown that by improving
activation levels, patient health outcomes and costs improve (Greene, Hibbard, Sacks,
Overton, & Parrotta, 2015). Additionally, online interventions and educational programs
have been reported as effective to improve diabetes-related outcomes and patient
activation (Lorig, 1996; Lorig et al., 2010).
Patient activation and hypertension. A study using interventions to improve
patient activation in a primarily black, hypertensive population, did not show positive
outcomes for the intervention but concluded that those with low activation improved
control better than those with higher activation scores (Ryvicker et al., 2013). In the
study by Ryvicker et. al. (2013), it was reported that those participants who had higher
activation levels, were younger aged, had lower blood pressures, higher health literacy,
higher education levels, fewer medications, and diabetes. Other studies also have had
difficulty finding patient activation interventions to be successful in reducing blood
pressures, having similar findings to the study by Ryvicker et al. (2013) with patient
activation (Thiboutot et al., 2013; Wagner et al., 2012).
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Patient activation and other illnesses. Other diagnoses, such as heart failure
(Gardetto, 2014; Shively et al., 2013), inflammatory bowel disease (Munson et al., 2009),
multiple sclerosis (Goodworth et al., 2014; Packer et al., 2015; Stepleman et al., 2010)
and orthopedic surgery (Skolasky, Mackenzie, Riley, & Wegener, 2009; Skolasky,
Maggard, Li, Riley, & Wegener, 2015), have been also been studied in association to
patient activation . These conditions may be similar to the population in chronic care
coordination who will participate in this study.
Gardetto (2014) evaluated patient activation in patients who had heart failure
attempting to link characteristics such as, confidence and emotional status, to activation
in those with chronic conditions plus heart failure. This study found a mediating
relationship between increased confidence and higher scores of activation, and partial
mediation of self-management behaviors (Gardetto, 2014). Those patients who were
more activated in their care had better heart failure outcomes, such as improved New
York Heart Association scores, functional capacity, and anxiety, than those who were
less activated (Gardetto, 2014). Shively et al. (2013) conducted a randomized controlled
study of an intervention to improve patient activation in heart failure patients and found
similar results to Gardetto (2015). The conclusion in both studies was that those patients
who were more activated had better health outcomes with their heart failure management
(Gardetto, 2014; Shively et al., 2013).
Patient activation and mental health. The literature searches for patient
activation and mental health turned up one article for PAM-MH, related to the tool
development. Subsequent searches revealed that mental health conditions tended to be
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included under the general term of “patient activation” and overall 14 studies were
evaluated which were identified on a reference list from www.insignia.com.
Patients with mental illness are noted to have reduced motivations to seek medical
care, are less apt to follow through with care, and less likely to be involved in decisions
related to their care (Muir-Cochrane, 2006). There is substantial evidence that those with
SMI have significant difficulties following through with their routine health care and
following healthy behaviors. For example, two studies noted that mortality rates are
higher in this population than those without mental illness (Brown, Birtwistle, Roe, &
Thompson, 1999; Saha, Chant, & McGrath, 2007). Patients suffering from SMI have
higher obesity rates (Allison et al., 1999; Green, Patel, Goisman, Allison, & Blackburn,
2000), lower activity levels (Daumit et al., 2005), higher cardiovascular complications
and high smoking rates (Goff et al., 2005).
An overall evaluation of patient activation in mental illness shows that activation
levels are low in a mental health population when depression is noted to be high, and
quality of life is low, according to the Short Form Quality of Life (SF-12) and Patient
Health Questionnaire (PHQ-9), a depression scale (Magnezi, Glasser, Shalev, Sheiber, &
Reuveni, 2014). The converse, high activation levels were associated with low levels of
depression and high levels of quality of life, was also shown in this study (Magnezi et al.,
2014). Moreover, a study by Sacks et al. (2014) indicates that activated patients have
better long-term outcomes than less activated patients. One-year follow-up of patients
who were more highly activated indicated that they also were managing their depression
as evidenced by higher remission rates and lower PHQ-9 scores (Sacks et al., 2014).
Chen et al. (2014) found that activation was greater when certain contextual factors, such
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as familiarity of provider and high levels of community resources are available. This
study gives evidence to the need for community resources and consistent care, which
enhance patient activation levels (Chen et al., 2014).
Four studies were identified that evaluate interventions, such as increasing
communication (Alegria et al., 2008), the use of the Health and Recovery Program
(Druss et al., 2010), and the use of web-based technology to increase patient activation
(Solomon, Wagner, & Goes, 2012; Solomon, 2010). Both communication and the use of
a defined program had positive effects on increasing a patient’s activation total scores,
increased attendance at follow-up appointments, but did not improve empowerment
(Alegria et al., 2008; Druss et al., 2010). Also, web-based technology was effective at
changing activation levels, and recommendations were made to target specific levels of
activation in these web-based interventions (Solomon et al., 2012; Solomon, 2010).
When considering patient activation and its relationship to chronic illness and mental
health diagnoses, having pharmacogenetic testing and medications prescribed based on
these results, no published literature was found.
Medication Adherence Literature Review
A search for the term “medication adherence” and “medication compliance” on
EBSCOhost with all databases chosen, yielded 13,726 and 14,320 respective articles.
Limiting the search to peer-reviewed scholarly articles and full articles available, the
result was 5,791 and 5,005”. Also, limiting the date from 2000 to 2015 only excluded 50
articles. When the terms “mental health” and “chronic illness” were added, the articles
were limited to 15. Through bibliographic references, additional articles were found
resulting in a review of 22 articles. Ten articles were found when the terms
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“pharmacogenetics or pharmacogenomics” were added to the search terms of
“medication adherence” and “medication compliance.” All of these articles were opinion
articles, and only one study was identified in these ten articles as relevant to this
dissertation topic.
Medication Adherence
Response to medication follows a known path; one must take the medication to
have a positive effect from medication. Medication adherence or compliance is a
multifaceted element within patient activation and includes a cascade of events that occur
within the patient and between the patient and other entities, such as the physician and
healthcare system (Dowell & Hudson, 1997). As described by Dowell & Hudson (1997),
medication adherence as a concept, includes the patient’s understanding and acceptance
of their medical condition, their ability to try the medication, and their acceptance or nonacceptance of taking the medicine.
Research indicates that those who accept their illness and accept their
medications are accountable (Dowell & Hudson, 1997). Additionally, studies report that
those who felt like they had more input in their medications, thus more engagement in,
had higher medication adherence rates (De Las Cuevas, Penate, & de Rivera, 2014). One
qualitative study evaluating low-income, chronically ill participants, describe that
medication compliance fell when patients did not have the feeling of sharing the decision
with their provider (Mishra, Gioia, Childress, Barnet, & Webster, 2011). When a person
feels there is little choice to take medication, psychological reactance occurs. This
psychological reactance can be an important factor in medication adherence of
antidepressants (De Las Cuevas, Penate, & Sanz, 2014). When self-efficacy was
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evaluated, there was no effect on medication adherence (De Las Cuevas, Penate, & de
Rivera, 2014). Interestingly, education given to patients regarding the medication and its
use was also ineffective at increasing medication adherence (Gray, Wykes, & Gournay,
2002).
Medication non-adherence is significant in mental health because it affects patient
outcomes, health care costs and increases depression relapses (Cantrell, Eaddy, Shah,
Regan, & Sokol, 2006; Geddes et al., 2003; Melfi et al., 1998). Overall, those who are
less educated, poor, and living in a rural area are less likely to be compliant especially
with antipsychotic medications (Martin-Vazquez et al., 2011). Furthermore, those who
are younger, have less understanding of their illness, and were diagnosed at an early age
with schizophrenia were less compliant (Sarath Chandra, Lokesh Kumar, Pramod Reddy,
& Pavan Kumar Reddy, 2014). In a study evaluating relapse in depression, three-fourths
of those who took their medications as directed did not relapse (Geddes et al., 2003).
Nevertheless, only half of patients who are taking antidepressants and are diagnosed with
major depressive disorder are compliant with their medication regime after three months
of use (Julius, Novitsky, & Dubin, 2009; Roca et al., 2011). Similarly, patients with
schizophrenia have a 50-60% compliance, and bipolar patients have the lowest reported
medication adherence at only 35 % (Colom et al., 2000; Lacro, Dunn, Dolder, Leckband,
& Jeste, 2002; Perkins, 2002).
In complex patients with multimorbid disease diagnoses and mental health issues,
medication adherence becomes more complex with each additional provider (Hansen et
al., 2014). Hansen et al. (2014) found that the threshold of difficulty arises as soon as
more than three providers are caring for a patient and prescribing medication.
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Commonly, patients who are this complex have more than one provider (Parchman,
Pugh, Noël, & Larme, 2002).
Provider expectations also have an impact on patient adherence and health
outcomes as described by Byrne and Deane (2011); Byrne, Deane, and Caputi (2008).
For instance, one study evaluated provider belief in the patient’s ability to be compliant
indicating a relationship of low expectations by providers yielding low adherence in
patients (Byrne et al., 2008). Byrne and Deane (2011) later evaluated if the relationship
between patient and provider affects medication adherence and found that a program
aimed at understanding medications could not only foster increases in medication
adherence but also enhance the patient-provider relationship.
The health care system, reimbursement, and other outside factors may also
influence a patient’s ability to remain compliant with medications (Dowell & Hudson,
1997). A qualitative study conducted by Kauppi, Hätönen, Adams, and Välimäki (2015)
in which focus groups were conducted with providers and patients, reported that
adherence was affected by the mental health system itself, relationships of providers, how
follow-up was carried out, and the ability to take into account a patient’s life view when
prescribing medications. Patients in the qualitative study stated that they would like to
know their provider and that this would help medication adherence. Additionally,
patients have a learning curve associated with new medications and the language of
healthcare (Kauppi et al., 2015).
Adverse effects may drastically affect medication adherence and are frequently to
blame for patient’s discontinuation of antipsychotic medication (Demyttenaere et al.,
2001). In depressed patients, discontinuation of treatment occurs because of side effects
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about 23-33% of the time (Hu et al., 2004). For example, the most common adverse
effects reported for the antidepressant Nortriptyline are dry mouth, blurred vision,
dizziness upon standing, and urinary symptoms, which are very similar to other
antidepressant medications. These contributed to medication discontinuation in the
genome-based therapeutic drugs for depression (GENDEP) study (Uher et al., 2009).
This study also noted that side effects occurred at the beginning of treatment and
decreased over time (Uher et al., 2009).
A German study evaluated patient medication adherence and serum blood levels,
finding inconsistencies that may be attributed to pharmacogenetic effects (Stieffenhofer
& Hiemke, 2010). For example, those who had genetically higher enzymatic activity,
which is called ultra-rapid metabolism (UR), through the CYP genetics, had lower serum
concentration of medication. Additionally, those who were genetically poor enzymatic
metabolizers (PM) had higher serum medication levels. Therefore, while patient
medication adherence may affect drug levels, pharmacogenetics may also play a role.
One sentinel study by Fagerness et al. (2014) evaluated insurance claims data for
patients who had received pharmacogenetic testing and medication guidance based on the
results of testing. When compared to a control group of patients without genetic testing,
the patients who received pharmacogenetic testing filed fewer insurance claims resulting
in a $546 savings per patient over a four months’ interval. Additionally, the patients who
had pharmacogenetic testing had claims data indicating increased medication compliance
when compared to the control group (Fagerness et al., 2014). It has been recognized that
the potential for this increased medication compliance could be related to the opening of
communications between the provider and patient regarding medications and their
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suitability based on genetic testing (Haga & LaPointe, 2013). However, no identified
studies have focused on communication, pharmacogenetics and medication adherence.
Pharmacogenetics in clinical practice
‘Pharmacogenetics,' a term coined by Friedrich Vogel in 1959, is the study of
drugs as they relate to a person’s genetic make-up (Eichelbaum, Ingelman-Sundberg, &
Evans, 2006; Vogel, 1959). Specifically, pharmacogenetics refers to the interaction of
drugs and the genetic makeup affecting the protein production in the cytochrome (CYP
450) enzymatic pathways of the liver (Ma, Lee, & Kuo, 2012). Consequently, this
affects drug metabolism by modification of enzyme activity within the pathway (Ma et
al., 2012). Pharmacogenetic testing is an innovative approach to finding the “right drug”
for the “right person” (Eichelbaum et al., 2006).
As previously noted, open communications are required between provider and
patient when genetic testing occurs. This communication is set in South Dakota state law
as of 2001 and includes appropriate informed consent from the patient regardless of study
participation. Standard of care when laboratory tests are ordered is that a provider
discusses the results with the patient and how the treatment plan may change based on the
ordered test. This study requires documentation of acknowledgment that medications
will be changed or confirmed based on the pharmacogenetic testing (South Dakota State
Legislature, 2001).
The Pharmacogenetics Research Network (PGRN) was developed in the year
2000 through the National Institutes of Health (NIH) and is composed of a multidisciplinary group established to evaluate pharmacogenomic impact on health
(Pharmacogenetic Research Network, 2015). It is through the PGRN that the Clinical
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Pharmacogenetic Implementation Consortium (CPIC) has put together evidence-based
guidelines for the use of pharmacogenetics in practice. The Dutch Pharmacogenetic
Working group (DPGW) is another consortium within the Netherlands who also have
evidence-based guidelines available for clinical practice. Between the two consortiums,
there are 78 evidence-based guidelines available to prescribing providers for guidance on
various medications in clinical practice (Whirl-Carrillo et al., 2012).
The use of the PharmGKB website at Stanford houses the CPIC and DPWG
clinical guidelines and continues to add to the science by conducting an analysis of
applicable publications which may be utilized in clinical practice (PharmGKB, 2015).
The availability of these resources has aided the acceptability and clinical use of
pharmacogenetics. For example, the Food and Drug Administration (FDA) has
approximately 120 medications which have metabolic relationships to specific genetic
pathways and are listed in patient medication pamphlets (FDA, 2014; Haga, Mills, &
Bosworth, 2014). Please refer to Appendix B for clinical guideline resources and
education in pharmacogenetics.
Other contributions to the clinical use of pharmacogenetics include decreasing
costs and increasing research interest and knowledge. Costs for processing
pharmacogenetic samples have decreased as technology has advanced, causing an
increase in research interest and clinical practice (Wu & Fuhlbrigge, 2008). These
research interests have focused on specific allele groups and their effect on medications.
Alleles are one of two forms of a gene that have occurred because of mutations,
substitutions or deletions of nucleotides or proteins and result in different physical traits
or phenotypes. Having blue eyes or having a CYP 450 pathway with poor metabolic
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enzyme activity, both represent phenotypes (Zhou et al., 2009). An allelic composition,
as it relates to pharmacogenetics, establishes the enzymatic abilities within the liver.
Most medications are metabolized, or activated through the CYP 450 enzymatic system,
and this accounts for how approximately 75% of medications are either activated or
cleared from the body. The remaining 25% are metabolized through alternative body
systems, e.g. kidney. (Furge & Guengerich, 2006; Guengerich, 2008).
Overall, pharmacogenetic testing includes evaluation of the genes responsible for
enzyme production throughout the CYP 450 liver metabolic pathways (IngelmanSundberg, 2001, 2004; Ingelman-Sundberg & Rodriguez-Antona, 2005). Each genetic
result provides a picture of how well or how poorly the enzyme functions in an individual
pathway to either activate the medication or degrade the medication for elimination.
Depending on the combination of alleles in the genes inherited by the parents, a person
may have normal metabolism, otherwise described as extensive metabolism (EM),
intermediate metabolism (IM), poor metabolism (PM), or ultra-rapid metabolism (UR)
(Ingelman-Sundberg, 2001, 2004; Ingelman-Sundberg & Rodriguez-Antona, 2005).
These results affect the ability of the liver to either convert a medication to its active form
or break down the medication for excretion. When the enzyme activity is increased, as in
ultra-rapid metabolism (UR), the medication will be quickly metabolized and the patient
may not see the benefit of the drug or will not have benefit of the drug’s positive effects
for the length of normal time metabolizers (EM) do (Mrazek, 2010b).
A clinical example of pharmacogenetics in practice was the point of an FDA
warning regarding children and the use of post-surgical codeine in children who are ultrarapid metabolizers at CYP 2D6 (Food and Drug Administration, 2013). When children
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who are ultra-rapid metabolizers at CYP 2D6 have normal doses of codeine, the
increased enzymatic activity converts codeine to morphine very quickly, which in turn
increases morphine blood levels causing respiratory decreases or arrest (Food and Drug
Administration, 2013), Poor metabolizers, on the other hand, are unable to break down
the medication to convert it to morphine and therefore, may not perceive the benefit of
the medication, plus may exhibit increases in side effects (Mrazek, 2010b; Mrazek et al.,
2014).
Pharmacogenetics in Mental Health
The primary CYP enzyme pathways involved in antipsychotic medication
metabolism in the liver include; CYP 1A2, CYP 2D6, CYP 3A4, and CYP 2C19. Within
each CYP pathway, variability of allelic composition exists. An allelic variant is an
alternate form of a gene; one allele is inherited from each parent. These allelic variations
influence the metabolism of a drug (Guengerich, 2008). Additionally, transporter and
receptor genes are important in psychotropic medication metabolism and transport and
include; OPRM1, SLC6A4, HTR2A, and COMT.
Indiana University website, http://medicine.iupui.edu/clinpharm/ddis/main-table,
lists medications according to their major pathway of excretion or activation.
Medications are classified as substrates, inhibitors, and inducers. A substrate is a
medication that passes through a specified CYP pathway, and the enzymatic activity
breaks down the medication. An Inhibitor is a medication that blocks or inhibits the
enzymatic activity from breaking down another medication that utilizes the same
pathway. An inducer is a medication that increases the activity of the enzyme causing an
increased rate of breakdown of a medication (Flockhart, 2007).
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The pharmacists working on the study have developed a table of psychotropic
medication utilized in this study and their associated CYP pathways (Appendix C).
Medications can be substrates, inhibitors or inducers of a CYP pathway. For example, a
substrate is a medication that utilizes the pathway, an inhibitor blocks the pathway for
other medications, and an inducer increases the enzymatic breakdown of the medication
(Zhou et al., 2009). A table related to medications for this study indicates psychotropic
medications that will be utilized in this study and denotes the CYP pathway utilized along
with if the medication is a substrate, inhibitor or inducer of a CYP pathway (Appendix
C). Magro, Moretti, and Leone (2012) described types of interactions such as Drug-Drug
Interactions (DDI), Drug-Gene interactions (DGI) and Drug-Drug-Gene Interactions
(DDGI). Commonly, Drug-Drug interactions are to blame for adverse drug reactions in
persons taking two or more medications (Magro et al., 2012). A recent study by
Verbeurgt, Mamiya, and Oesterheld (2014) noted that in addition to DDI there are DGI,
and DDGI that take place. These interactions are much more frequent than most realized.
DDI’s are caused when two drugs alter another drug’s effect on the body or interfere with
metabolism, distribution or excretion of another drug. DGI’s are an interaction between
the drug and genetic makeup of the person, such as interference in the liver’s CYP 450
enzymatic pathways (Verbeurgt et al., 2014). DDGI’s occur when there are drug-drug
interactions and drug-gene interactions affecting several CYP 450 pathways (Verbeurgt
et al., 2014). This study notes that DDI’s account for 66.1% of interactions, but that the
remaining 33% were associated to DGI, and DDGI’s (Verbeurgt et al., 2014).
Accounting for this information, it suggests that pharmacogenetic testing may increase a
provider’s ability to prescribe a drug that will not cause adverse effects.
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The pharmacogenetic report will include the genetic results and medication
changes recommended by a pharmacist team. The provider and patient communication
will include an acknowledgment by the patient that their medications are based on their
genetic profile. The reports will include suggestions individualize to the patient’s current
medication list and genetic profile. For example, if a patient has a resulting genetic panel
that results in poor metabolism of the CYP 2D6 pathway and is taking fluvoxamine,
which is metabolized primarily by this pathway, an alternate medication recommendation
would be provided. Additionally, the report will list medications that should be avoided
with this patient.
Gaps between genetics and behavioral outcomes
Very little research has focused on the influence of having genetic testing on
patient behavior, specifically pharmacogenetic testing. Haga and LaPointe (2013) have
speculated that the act of pharmacogenetic testing will increase a patient’s medication
adherence. Additionally, Haga and LaPointe (2013) point out other positive impacts of
pharmacogenetic testing such as less need for medication dosing adjustments, fewer
changes in medications, fewer side effects, and the potential of less time to therapeutic
outcomes. These factors may contribute to medication adherence after pharmacogenetic
testing. However, there is only one identified publication that has addressed these two
topics together using pharmacy refill data (Fagerness et al., 2014).
Three studies addressed medication adherence in patients who have had genetic
testing, two studies evaluated risk genes and medication adherence, while one evaluated
pharmacogenetic testing and insurance information on medication refill data (Charland et
al., 2014; Fagerness et al., 2014; Grant et al., 2009). Grant et al. (2009) conducted a
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survey of participants in type 2 diabetes trials with and without a diabetes and reported
that they would be more likely to have higher motivation to change their lifestyle if they
had a ‘high risk’ gene for diabetes. Additionally, participants reported that they would be
‘much more motivated’ to be compliant with their medications if they had the high-risk
gene (Grant et al., 2009). Additionally, Charland et al. (2014) evaluated adherence to
statin medications after risk testing of the KIF6 gene which shows an increased risk for
congestive heart disease, finding that adherence increased with the knowledge of the
result of this genetic testing. The difference here is that the KIF6 gene is a risk gene and
does not affect medication metabolism. However, the finding implies that having the
genetic result of increased risk, increases a person’s motivation to become more
compliant. One recent study evaluated retrospective health claims and concluded that
those participants who had pharmacogenetic testing were more adherent to their
medication as noted by medication refill data (Fagerness et al., 2014).
Medication adherence and patient activation have been noted to be low in patients
with mental health disorders (Gunn et al., 2012; R. Sacks et al., 2014; Whooley et al.,
2008). As defined by Hibbard (2008) activation refers to how engaged one is in
managing his or her healthcare and can change over time. It follows that if
pharmacogenetics may improve a patient’s medication adherence, which is a component
of patient activation, overall activation may also improve. The amount of activation a
patient may have in his or her healthcare is variable based on patient interest, skills, and
the capacity to understand the diagnoses (Von Korff et al., 1997).
Patient activation improves not only medication adherence but also health
outcomes. When a patient is activated or engaged in their healthcare, increases in health-
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related behaviors are noticed including improved diet, exercise and obtaining
preventative screening tests (Hibbard et al., 2004). Four studies indicated that high
patient activation measures correlate to better health outcomes in biometric indicators of
health such as blood pressures, HgA1C levels, cholesterol levels, and body mass index
(Hibbard & Greene, 2013; Rogvi et al., 2012; R. Sacks et al., 2014; Skolasky et al.,
2011). To date, there are no published prospective studies identified which have studied
patient response to pharmacogenetic testing as a relationship to medication adherence and
patient activation.
This research study seeks to address the gaps in the literature found regarding
patient activation, medication adherence and pharmacogenetic testing in a mental health
and chronic illness patient population. The purpose of the study is to compare the
outcomes of patient activation and medication adherence before and after medication
recommendations have been made utilizing pharmacogenetic testing information in a
chronic illness and mental health population. Research is needed to explore
pharmacogenetics and potential behavioral changes. No published studies were found by
this author addressing pharmacogenetics and patient activation. Additionally, only one
published study was found by this author which examined medication adherence as the
relationship of medication refill data to pharmacogenetics. No published studies were
identified by this author evaluating pharmacogenetics in patients with complex medical
and medication backgrounds including mental health diagnoses and chronic illnesses.
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Theoretical Framework
Davies et al. (2010) introduced a theoretical framework targeted to the practicing
clinician. It was developed by evaluating challenges that clinicians face when choosing
antipsychotic medications. The challenges are that a provider must be aware of and
knowledgeable regarding pharmacology of drugs, molecular genetics of drug targets, and
genetics of drug metabolism to prescribe medications according to genetics. The
conceptual framework emphasizes the patient outcomes related to medication adherence,
side effects of medications and effectiveness of the medications (Davies et al., 2010).
Within this conceptual framework, medication monitoring, medication planning,
molecular genetics of drug absorption and metabolism and patient outcomes are
described. These elements will be incorporated into Orem’s theory of self-care to
provide the framework and the theoretical basis for the study. This study will be
addressing the molecular genetics of drug targets and metabolism as they relate to patient
adherence, activation and thus patient outcomes.
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Figure 1. Conceptual framework incorporating pharmacologic findings and
pharmacogenetic evidence about atypical antipsychotic medications (AADs) into
advanced psychiatric nursing practice Davies, M. A., Conley, Y., & Puskar, K. (2010).
Incorporating evidence from pharmacologic and pharmacogenetic studies of atypical
antipsychotic drugs into advanced psychiatric nursing practice. Perspectives of
Psychiatric Care, 46(2), p.99

Nursing Perspective
Dorothea Orem’s Self-Care Deficit Theory (SCDT) theoretical emergence came
from influences of philosophers such as Aristotle, Thomas Aquinas, Harre and Wallace
and influenced the assumptions underlying her theory (Orem, 2006). In Orem and Taylor
(2011, p. 36)’s last reflections on her philosophic determinants, it was expressed that she
followed a “moderate realism”, which was clarified as a practical scientific method, with
applications of nursing science to practical reality. In an effort to define nursing science,
the grand theory of SCDT emerged (Orem & Taylor, 1986, 2011).
Three mid-range theories, which are interrelated, comprise the grand theory of
SCDT. These intertwined theories include concepts, assumptions about the theory, and
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interrelationships between the theories. The three theories are; the Theory of Self-Care,
Theory of Self-Care Deficit, and the Theory of Nursing Systems (Parker & Smith, 2010).
Figure 2 illustrates how the Theory of Self-Care is a subset of the Theory of Self-Care
Deficit, which is a subset of the overarching
Theory of Nursing System.

Theory of Nursing System

Theory of Self-Care Deficit

Theory of Self-Care

Figure 2. Constituent theories, the self-care deficit theory of nursing.
Orem, D. (1995). Nursing Concepts of Practice (5th Ed.) St. Louis: Mosby. (p.172)

Theory of Self-Care
The ideas behind self-care began with the simple question, “Why do people need
nursing?” (Renpenning & Taylor, 2003, p. 261 of 6936). The term was coined in 1956
when Orem was describing nursing in an Indiana State Health report (Orem, 1971; Orem,
2006). The theory of self-care has three central concepts which include; self-care, selfcare agency and self-care requisites, as depicted in Figure 3 below (Denyes et al., 2001;
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Nursing Development Conference Group, 1979). Renpenning and Taylor (2003, p. 3816
of 6936) wrote from “personal knowledge”, one of the emergent definitions of self-care
as;
“Self-care is conceptualized as the personal care that human beings require each
day and that may be modified by health care, environmental conditions, effects of
medical care and other factors.”

Person(s) in Life Situations
Managing and Attending
To Self

With Requirements to
Regulate Functioning
And Development

Self-Care
Requisites

With Power to Engage
In Self-Care

Self-Care
Agency

Engaging in Action
To Meet Regulatory
Requirements

Self-Care

Figure 3. Denyes, M., Orem, D., & Bekel, G. (2001). Self-care: A foundational science.
Nursing Science Quarterly, 14(1), p.49.
Self-Care. The concept of self-care identifies the “self” as both the entity
performing the action or the “action agent” and the recipient of care. Self-care is
purposeful behavior, which contributes to the overall wellness of an individual. The
presuppositions of self-care are that it is a learned, voluntary behavior and responsibility
or a right of the individual to maintain health and wellness (Denyes et al., 2001; Nursing
Development Conference Group, 1979).
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The propositions include understanding self-care from three perspectives that
contribute to overall self-care and include; (a) conditioning factors, (b)
psychophysiological factors contributing to health and disease states, and (c) behavioral
resources and demands (Denyes et al., 2001). Conditioning factors include; having
abilities related to understanding self, having a self-concept, understanding family and
social positions, along with maturity levels. Psycho physiological factors which
contribute to health include self-care maintenance or the ability to maintain balance
within the self, ability to perform tasks to maintain health, and ability to obtain or have
knowledge of what needs to be completed to maintain health. For example, anything that
disrupts the balance may cause illness and affect one’s abilities of self-care. Moreover,
self-care behavioral resources that include one’s motivation, and use of resources
(Nursing Development Conference Group, 1979).
Self-care requisites. Self-care requisites are generalized actions required to
maintain a purpose. Additionally, within self-care, there are three main categories of
self-care requisites including; universal, developmental and health-derived (Orem, 2001;
Renpenning & Taylor, 2003).
Universal self-care requisites include commonalities to all humans at all ages,
such as the need to sleep, eat, and exercise. Nurses have the ability to identify a patient’s
maturation process and adapt nursing interventions towards those developmental
requisites. Developmental health care requisites occur across the lifespan and are the
changes one has as one ages including cognitive and affective changes. Health-derived
requisites are biologically based changes to structure and function of the body and
represent a need for nursing care (Orem, 2001; Renpenning & Taylor, 2003; Taylor,

40
Renpenning, Geden, Neuman, & Hart, 2001). Orem (2001) identified six types of healthderived requisites including; the ability to seek and gain medical assistance, identifying
changes in one’s health status, following through with prescribed treatments, awareness
of and attendance to negative effects of treatment, adjusting self-image as health status
changes, and living with health conditions as they arise (Orem, 2001).
Renpenning and Taylor (2003) published collections of Dorothea Orem’s
unpublished writings notes which had been presented at meetings. This collection also
refers to “therapeutic self-care demand” as a requisite. Orem defines this as
“ care measures or self-care or dependent-care practices which result from
investigation of questions about how self-care requisites can be met under
prevailing conditions” (Renpenning & Taylor, 2003, p. 3930 of 6936).
Therefore, when self-care demand is overwhelming to the person’s self-care capabilities,
nursing assistance is needed (Orem, 2006).
Self-care agency. Self-care agency is the power and ability to care for the self,
and therefore nursing agency is the capability, knowledge and insight into the patients
needs as self-care agents with deficits (Renpenning & Taylor, 2003). Motivation and
motives are the basis for self-care agency along with action. Motivation, however, is a
complex concept with two actionable concepts; (a) there must be a deliberate goal
seeking action; (b) There must be a relationship between the motivation and deliberate
action (Renpenning & Taylor, 2003). In addition, there are six conditions that may
promote self-care agency; (a) people must be knowledgeable to see what is good and bad
in their pursuit of a goal; (b) people must have a reason that is personalized as desirable;
(c) people need time to formulate and visualize a plan of action; (d) people should reflect
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on their actions to determine suitability of the actions; (e) people should end their
reflection time; (f) people must be responsible for their choice of action to attain the goal
(Orem, 1987; Renpenning & Taylor, 2003).
Study framework. Orem’s Theory of Self-care, patient activation, medication
adherence and pharmacogenetic framework are used as the study’s complete framework
to help describe the behavioral components of self-care after pharmacogenetic testing,
and medication changes have been implemented. This study will measure Patient
activation (PAM-MH) and as evidence of the components of Self-Care, Self-Care
Agency, and Self-Care Requisites. For the pharmacogenetic testing framework for this
study see Figure 4.

Figure 4. Patient activation as evidence of Self-Care.
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Summary
This literature review and discussion of theoretical basis have identified the
concepts that are significant to the design and implementation of this study. The purpose
of the study is to compare the outcome of patient activation before and after medication
recommendations have been made utilizing pharmacogenetic testing information in a
chronic illness and mental health population.
Studies have been conducted in patients with significant mental illness with
regards to patient activation. However, no studies identified by this author have
addressed patient activation in patients who have had pharmacogenetic testing.
Pharmacogenetics is gaining clinical acceptance as evidence for its applications within
the mental health population grows. No research exists related to behavioral outcomes of
pharmacogenetic testing in this population. Therefore, this study is designed to address
the gaps in the literature as they relate to aspects of patient activation in patients with
serious mental illness after pharmacogenetic testing and implementation. This study will
add to knowledge and understanding of behavioral aspects of pharmacogenetic testing
and medication planning based on testing, patient activation and medication adherence.
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CHAPTER 3

DEPRESSION OUTCOMES IN CARE COORDINATION, PRIMARY CARE AND
PSYCHIATRY PATIENTS AFTER PHARMACOGENETIC TESTING.
Introduction to study changes
The study of patient activation in mental health patients after having
pharmacogenetics care in a care coordination population was discontinued in January
2016 due to an administration reason. When the study concluded, there were 26
participants with 100 required, and enrollment was progressing slowly. This chapter
discusses the combination of data from three studies. The purpose of this dissertation
study was to evaluate by provider types of care coordination, primary care and
psychiatry, the change of depression severity (PHQ-9), depressive symptoms (QIDSSR16) and quality of life (SF-36) over time (T1-T3) in a population of patients diagnosed
with MDD or DDNOS after having had pharmacogenetic testing.
The data from the care coordination study was combined with data collected from
two additional studies that evaluated pharmacogenetics testing in people diagnosed with
depression. All studies included a pharmacist guided medication recommendation for
each participating patient, and these recommendations were given to providers in a report
called the pharmacogenetics report (PGXr). The term “pharmacogenetics care” will be
used to represent the process of medication recommendation reporting based on genetics
and genetic testing which occurred in all of these studies. This process includes the fact
that by entering the study and having genetic testing, study participants’ medications for
depression were managed based on their genetics. All studies were conducted with
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patients who were diagnosed with new or current major depressive disorder (MDD) or
depression disorder- not otherwise specified (DDNOS). The similarities and differences
of these studies will be explained.
The main differences between the three studies was the type of provider managing
the patient’s depression. One study evaluated a population of patients who had
specialists, psychiatrists, managing their depressive disorder. This study will be referred
to as ‘psychiatry’ throughout this document. While the other two studies focused on
patients, who were managed by primary care providers. The care coordination study
focused on patients with complex medical concerns under the management of a primary
care provider and the patient was participating in care coordination. The care
coordination study utilized a nurse or social worker to help navigate through the health
system and manage care. The third study had depression management through primary
care, and will be referred to as the ‘primary care’ study. While patient activation was a
component of the care coordination study, it was not included in the other two studies.
Therefore, no patient activation data will be analyzed.
All participants completed the same questionnaires including, a) an assessment of
depression severity, Patient Health Questionnaire 9 (PHQ-9), b) an assessment of
depression symptoms, The Quick Inventory for Depressive Symptoms- Self Report
(QIDS-SR16) and c) an assessment of quality of life, The Short Form 36 (SF36).
Additionally, questionnaire collection was completed on the same timeline and visit
schedules in all three studies. Completion of questionnaires occurred at baseline (T1), at
the time the pharmacogenetics medication recommendations report (PGXr) was returned
to their provider, (T2), and one month after medication changes were made (T3).
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Demographic information such as age, marital status, insurance type, number of mental
health diagnoses, and number of chronic health conditions were also collected.
These three depression studies were designed to evaluate the use and impact of a
comprehensive pharmacogenetic report prepared by genetic pharmacists in the three
settings. All three groups received pharmacogenetic testing, and providers were given a
pharmacists guided report with medication recommendations based on the patient’s
genetics. Patients acknowledged that they would have medications modified based on
this genetics report during the consenting process, and subsequent provider discussions
regarding the report.
The genetic reports took into account each patient’s genetic variants as they relate
to their enzyme activity of drug metabolism. The reports also included information
related to interactions between genes and other medications, such as, drug-drug, druggene and drug-drug-gene interactions (Magro et al., 2012; Verbeurgt et al., 2014). The
testing focused on genetic pathways associated with antidepressant and antipsychotic
medications, see appendix A. This report included a list of medications classified into
three categories, “use as recommended”, “use with caution”, or “not recommended”, for
each patient’s medication list. This report was given to the providers at four weeks or at
12 weeks in two of the studies. The care coordination study patients had reports prepared
for providers at four weeks without randomization.
In summary, these three studies shared a similar population of patients all of
which had a diagnosis of depression (MDD or DDNOS), data from the PHQ9, QIDS-SR,
and the SF-36, which were completed at the same intervals, and all studies had
pharmacogenetic testing with comprehensive pharmacogenetic care (PGXr). These
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likenesses allowed for data combination and analysis. The three studies are described in
detail. (Table 1) describing similarities and differences of the three studies.
Table 1
Comparison of three provider types
Study

Primary Care

Specialists Care
(Psychiatry)

Care Coordination
Study

population

outpatient primary
care

outpatient
psychiatric care

outpatient primary
care (care
coordination
participants)

diagnoses

depression (MDD
or DDNOS)

depression
(MDD or
DDNOS)

*depression, bipolar,
schizophrenia

PHQ9

PHQ9

PHQ9

QIDS-SR16

QIDS-SR16

QIDS-SR16

Quality of life
questionnaire

SF-36

SF-36

SF-36

Randomization

PGXr received by
provider at 4 weeks
or 12 weeks

PGXr received
by provider at 4
weeks or 12
weeks

No randomization
occurred.

depression
questionnaire
symptoms
questionnaire

Care Coordination study
The initial dissertation study is referred to as the care coordination study and was
evaluating mental health patients’ activation in a care coordination population after
receiving pharmacogenetic care. This study enrolled patients with MDD or DDNOS. In
addition to these depression diagnoses, these care coordination participants had
significant chronic illnesses and other mental health diagnoses in addition to depression.
Patients typically enter care coordination through recommendations made by their
primary care providers having met the criteria for the program. Care coordination
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patients were accepted into the care coordination program based on the number of
hospitalizations, number of medications and chronic diagnoses. Tier selection based on
hospitalizaitons and providers caring for the patient are presented (Table 2). If a patient
has more than two medications with a visit to the emergency department, and, at least,
two providers, the patient could be admitted to the lowest level of care coordination. The
highest level of care coordination includes patients who were taking more than nine
medications, has had two or more emergency room visits, two or more inpatient
hospitalizations, and was seeing eight or more providers. The care coordination patients
had a nurse and a social worker assigned to them to help navigate the health care system.
Table 2.
Care Coordination Tiers

Tier 1

Tier 2

Tier 3

Tier 4

1 - 2 medications
1* ER visit

3 – 4 medications
1 ER visit

0 IP Admits

1 IP Admit

6- 8 medications
2 ER visit
2 IP Admits,
including 1
readmit

9 + medications
2+ *ER visits
2+ IP Admits
including 2
readmits

1- 2 physicians
providing services

3- 4 physicians
providing services

*Hx: one diagnosis
and/or complaint

Hx: 2-3 diagnoses
and/or complaints

5 –7 physicians
providing
services
Hx: 4 – 5
diagnoses and/or
complaints

8+ physicians
providing
services
Hx: 6 +
diagnoses and/or
complaints

*Hx = History; ER = Emergency Room
Primary Care study
Primary care providers who manage patients with depression were eligible to
refer patients to this study. All participants continued to work with their primary care
providers for management of their depression. Patients who qualified for this study must
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have scored ten or greater on the Patient Health Questionnaire (PHQ-9) indicating current
depressive symptoms and the need for treatment alteration or dose escalation. A high
score on the PHQ9, indicates more severe depression. Participants had a baseline
assessment of their depression severity (PHQ9), depressive symptoms (QIDS-SR16) and
quality of life (SF-36). This study was a six-month study, with blinded randomization.
Patients were randomized to either having their provider receive their report at four
weeks or 12 weeks, (Table 3).
Psychiatry
The Specialists study ‘psychiatry’ included the same population of patients.
However, these patients were being provided care by psychiatry instead of primary care.
All other assessments and randomizations were the same. Data collection and timing
were similar in all studies (Table 1) (Table 3).
Randomization in two of the three studies
Participants in the primary care and psychiatry studies were randomized to
receive the PGXr at four weeks or twelve weeks. Participants who were randomized to
the four-week arm of the study, were assessed by their first and third visits; baseline (T1),
and one month after recommendations had been made (T3). The participants who
received randomization at 12 weeks were assessed at baseline (T1), at the time they
received PGXr at 12 weeks (T2) and one month after receiving their reports (T3). All
patients completed the same assessments including the PHQ-9, QIDS-SR, and the SF36
at each visit. Evaluations and timelines are presented in (Table 1) and (Table 3) for the
evaluations and timeline. All three studies were approved by the health systems local
Institutional Review Board. See appendices D for the Institutional Review Board
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approval, E for the Informed consent and supporting documents, F for the patient
invitation letter, G for IRB approval Amendment 2.
Table 3
Data collection time-points
ALL STUDIES COLLECTED
1 month after results
Baseline

PGX results

returned

Assessment

T1

T2

T3

PHQ-9

x

x

x

QOL

x

x

x

QIDS-SR

x

x

x

T1 = Time 1, T2 = Time 2, T3 = Time 3
Problem statement
Depression is a significant problem in the United States, and many who suffer
from depression do not achieve remission of depressive symptoms and, or, develop side
effects from medications (Ishak et al., 2013; World Health Organization, 2015). In a
literature search, there were three sentinel studies identified, indicating comparisons of
primary care and psychiatry providers, but no studies were identified that evaluated
depression outcomes of patients participating in care coordination with comparisons to
primary care or psychiatry patients (Gaynes et al., 2005; Gaynes et al., 2007; Simon, Von
Korff, Rutter, & Peterson, 2001).
A study by Simon et al. (2001) concluded that both primary care and psychiatry
patients had improvement in their depression and quality of life scores, and reported that
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there were not any differences of depression severity between the two groups (Simon et
al., 2001). Gaynes et al. (2007) findings supported that primary care and psychiatry
providers have similar outcomes and have patients with similar depression severity. On
the other hand, conflicting information was found regarding suicidal ideation. The study
by Gaynes et al. (2005) indicated that those patients who were managed by psychiatrists
had a higher incidence of suicidial ideation and past suicide attempts compared to
primary care patients, but then found later that suicidal ideation was equal in both
provider groups. This study also reported that primary care patients were less likely to
self-select as having a depressed mood and had the inability to experience pleasure, i.e.,
anhedonia, indicating a potential to under report symptoms (Gaynes et al., 2005).
The study by Simon et al. (2001) also found that there were deficiencies in both
primary care and psychiatry providers, such as poor follow-up with patients after they
leave the clinic. The study also recommended adding more care management options to
improve patient compliance and potentially outcomes (Simon et al., 2001). In fact, a
study completed earlier by the same group identified that when a patient has systematic
follow-up from a care manager, depression did improve (Simon & Ludman, 2000).
However, a comparison of care management such as care coordination to both primary
care and psychiatry was not identified in a literature review. The literature review did not
reveal any commparisons of baseline differences in depression, or changes over time
between a care coordination population compared to those patients who are managed by
primary care or psychiatry.
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Table 4
Comparison of three studies
Study

Primary Care

Specialists Care
(Psychiatry)

Care Coordination
Study

population

outpatient primary
care

outpatient
psychiatric care

outpatient primary
care (care
coordination
participants)

diagnoses

depression (MDD
or DDNOS)

depression
(MDD or
DDNOS)

*depression, bipolar,
schizophrenia

PHQ9

PHQ9

PHQ9

QIDS-SR16

QIDS-SR16

QIDS-SR16

SF-36

SF-36

SF-36

depression
questionnaire
symptoms
questionnaire
Quality of life
questionnaire

PGXr received
by provider at 4
Randomization
weeks or 12
weeks
*Care coordination allowed additional diagnoses as listed
PGXr received by
provider at 4 weeks
or 12 weeks

No randomization
occurred.

Purpose of this study
The purpose of this study was to evaluate by provider types including care
coordination, primary care and psychiatry, the change of depression severity (PHQ-9),
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a
population of patients diagnosed with MDD or DDNOS after having had
pharmacogenetic testing.
Research questions
1.

Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in depression severity (PHQ9) over time (T1-T3)
based on the type of provider?
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a. Hypothesis 1: Depression severity scores (PHQ9) among patients who
receive care coordination will decrease over time.
b. Hypothesis 2: Depression severity scores (PHQ9) among patients who
receive care by a Primary care provider will decrease over time.
c. Hypothesis 3: Depression severity scores (PHQ9) among patients who
receive care by a Psychiatrist will decrease over time.
2. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in depression symptoms (QIDS-SR16) over time
(T1-T3) based on provider type?
a. Hypothesis 1: Depression symptom scores (QIDS-SR16) will decrease
over time (T1-3) among patients who receive care coordination.
b. Hypothesis 2: Depression symptoms scores (QIDS-SR16) will decrease
over time (T1-T3) among patients who receive Primary care services.
c. Hypothesis 3: Depression symptoms scores (QIDS-SR16) will decrease
over time (T1-T3) among patients who receive care through psychiatry.
3. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in the physical components (physical functioning,
role physical, bodily pain, general health) of the SF-36 scale by provider type?
a. Hypothesis 1: Overall physical component scores (PCS) of the SF-36 scale
will be highest in psychiatry and primary care, and lowest in care
coordination.
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b. Hypothesis 2: When comparing by provider types, physical functioning
scores in the SF-36 scale will be the highest in psychiatry and primary
care and the lowest in care coordination.
c. Hypothesis 3: When comparing by provider types Role Physical scores in
the SF-36 scale will be highest in psychiatry, and primary care and lowest
in care coordination.
d. Hypothesis 4: When comparing by provider types, Bodily Pain scores in
the SF-36 scale will be highest in psychiatry and Primary care and lowest
in care coordination.
e. Hypothesis 5: When comparing by provider types, General Health scores
in the SF-36 scale will be highest in psychiatry and Primary care and
lowest in care coordination.
4. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in the mental components (vitality, social function,
role emotion, and mental health) of the SF-36 scale by provider type?
a. Hypothesis 1: When comparing by provider types, mental composite
scores of the SF-36 scale will be highest in primary care and care
coordination and lowest in psychiatry. Hypothesis 2: When comparing by
provider types, Vitality scores in the SF-36 scale will be the highest in
primary care and care coordination and lowest in psychiatry.
b. Hypothesis 3: When comparing by provider types, Social function scores
in the SF-36 scale will be the highest in primary care and psychiatry and
lowest in care coordination.
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c. Hypothesis 4: When comparing by provider types, Role Emotional scores
in the SF-36 will be the highest in primary care and care coordination and
lowest in psychiatry.
d. Hypothesis 5: When comparing by provider types, Mental Health scores
will be the highest in primary care and care coordination and lowest in
psychiatry.
5. How does the study population’s genetic phenotype (poor metabolizer,
intermediate metabolizers, ultra-rapid metabolizer) in all provider types compare
to the general population genetic phenotypical frequency rates?
Summary of study changes
This study evaluated the provider types of care coordination, primary care and
psychiatry providers, changes in depression severity (PHQ9), depression symptoms
(QIDS-SR16) and quality of life (SF-36) over time after having pharmacogenetics
testing. Data from three studies were combined in a population of patients newly or
currently treated for MDD or DDNOS. All participants had a personalized pharmacist’s
guided report based on their current medications and genetic testing. The similarities of
the three studies in patient population, questionnaire completion and timing of visits were
similar to allow comparisons between patients managed by each of the three provider
types.
Literature Review
This review will provide a brief summary of the literature found to support the
need for this study. The purpose of this study was to evaluate by provider types of care
coordination, primary care and psychiatrists, the change of depression (PHQ-9),
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depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time in a population
of patients diagnosed with MDD or DDNOS not in remission after having had
pharmacogenetic testing. The following topics were explored in this literature review
including depression as was related to the following areas; the prevalence, characteristics
in primary care and psychiatry practices, and care coordination and quality of life.
Depression
Worldwide 350 million people suffer from depression, and in the United States,
the number suffering from depression is approximately 40 million (World Health
Organization, 2015). This number represents primarily women and is the cause of
approximately 800,000 suicides every year (World Health Organization, 2015). Pratt and
Brody (2008) note that depression varies by socioeconomic status, age, sex and race.
Regarding socioeconomic status, those who fell below the federal poverty level and were
women age 40-59 had the highest incidences of depressive episodes (Pratt & Brody,
2008). Depression causes functional changes in one’s ability to perform daily activities,
get along with others and work (Pratt & Brody, 2008). The Diagnostic and Statistical
Manual of Mental Disorders-Revised 5th edition criteria includes the notation of positive
indicators of five out of nine symptoms such as depressed mood, decreased interest or
pleasure, changes in weight, changes in sleep, changes in activity, increased fatigue,
increased guilt, changes in concentration and suicidality (American Psychiatric
Association, 2013). Additionally, poor quality of life has been shown to be associated
with depression and reported to be an important factor related to understanding
depression (Bonicatto, Dew, Zaratiegui, Lorenzo, & Pecina, 2001; Doraiswamy, Khan,
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Donahue, & Richard, 2002; Papakostas et al., 2004; Saarijarvi, Salminen, Toikka, &
Raitasalo, 2002; Trivedi et al., 2006)
10
A literature review was conducted using the terms ‘depression’ and ‘psychiatry or
psychiatric or mental health’ and ‘primary care’, through EBSCOhost with all databases
chosen, which yielded 2,668 articles. Limiting the search to full-text, and between the
dates of 2010-2016, the number of articles resulted in 732. Topics of maternal mental
health, perinatal mental health, child *.*, and veterans were excluded, 552 articles were
returned. From these articles three sentinal articles were identified which totaled 13
articles reviewed.
Many studies identify a need to meet evidence-based standards in primary care
and a need to improve training in primary care (Mechanic, 2014). The literature search
was rich with articles regarding primary care and its ability to identify patients (Lemelin,
Hotz, Swensen, & Elmslie, 1994), screen (Tiemens, VonKorff, & Lin, 1999), treat and
refer to psychiatry (Ferguson, 2000). Indirect comparisons of provider types have
reported that specialty care was more expensive but most effective in treating depression
(Sturm & Wells, 1995). One study, which lacked sample size, showed significance
toward the superiority of primary care to specialty care for treatment of depression (Scott
& Freeman, 1992). Direct comparisons of primary care and psychiatry have been
conducted in regard to depression severity and outcomes (Gaynes et al., 2005; Gaynes et
al., 2007; Howland, 2008; Rush, 1993; Simon et al., 2001), and medication prescribing
(Mayor, 2015).
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The earliest comparisons of primary care and psychiatry patients indicate that
initial depression severity and number of medical diagnoses were similar in both provider
types (Simon et al., 2001). This study also concluded that over time both primary care
and psychiatry patients had improvement in their depression and quality of life scores,
but there were not any differences between them (Simon et al., 2001). Also, it was
observed that there were deficiencies in patient care by both groups, as exampled by poor
follow-up with providers. Furthermore, this study added that more care management
options would improve patient compliance (Simon et al., 2001). In fact, a study
completed earlier identified that when a patient has systematic follow-up from a care
manager, depression did improve (Simon & Ludman, 2000). However, a comparison of
care management such as care coordination to both primary care and psychiatry has not
been reported.
Two recent studies published by Gaynes et al. (2005); Gaynes et al. (2007)
assessed the differences in those patients who sought treatment management by a primary
care provider or by a psychiatrist. These studies had similar results to Simon et al.
(2001), reporting that the depression severity between the two groups was similar.
However, the study by Gaynes et al. (2005) indicated that those patients who were
managed by psychiatrists had a higher incidence of suicidal ideation and past suicide
attempts compared to primary care. In the 2005 study by Gaynes et. al, primary care
patients were also less likely to self-select having a depressed mood and anhedonia. The
next study Gaynes et al., (2007) conducted included 1,000 more participants and asked
similar questions. This subsequent study confirmed findings of equal depression
severity, and depression symptom distribution in both primary care and psychiatry groups
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(Gaynes et al., 2007). However, when suicide was assessed, it was also found to be equal
in both groups for suicide attempts and suicidal ideation, which contradicts the previous
report that psychiatry had higher suicide rates (Gaynes et al., 2007)
Care coordination and depression
Literature reviews of EBSCOhost with all databases chosen for the words ‘care
coordination’, and ‘depression’ returned 377 articles. When children and veterans were
excluded 199 articles were returned and ‘health to home’ was added a return of 7 articles
which were unrelated to the dissertation topic were returned. Limiting to full-text
available and peer review, decreased the 199 articles to 100. No studies were identified
specifically indicating depression care in care coordination. Some topics revealed ‘casemanagement’, ‘stepped-care’, ‘collaborative models’. Searches of these and article
bibliographies such as from the American Nurses Association and the Institute of
Medicine discussions regarding care coordination, 17 articles for this review were
identified. Because few results returned articles specific to care coordination, casemanagement or care management will also be discussed.
While case-management is slightly different than care coordination, casemanagement provides information regarding improving outcomes for patients associated
with guidance within the health care system (Gensichen et al., 2013). Collaborative Care
is another model using professional collaboration, evidence-based protocols and has a
focus on long-term outcomes of patients with chronic conditions (Gunn et al., 2012).
Case-managers can be master’s prepared nurses, who orgainize and coordinate care
services to maintain continuity of care and minimize costs . Care coordination has many
more definitions identified and encompases more scope than case-management
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(McDonald et al., 2014; McDonald et al., 2007; Schultz, Pineda, Lonhart, Davies, &
McDonald, 2013). Because of the large overlap of practice and extreme similarities
between case-management and care coordination, case-management was included in the
literature review.
Ekers et al. (2013) conducted a meta-analysis of published studies which used
collaborative care model to evaluate its effectiveness in managing patients with
depression. This meta-analysis evaluated the results of 14 randomized studies and
reported that patients who are managed by nurses and have long-term chronic illnesses
have better outcomes than without nurse management (Ekers et al., 2013). Another study
showed improvements in depression-free-days when case-management for depression
was used in small practice settings (Gensichen et al., 2013). A more recent study of care
management for depression, found that patients involved in collaborative depression care
had decreases in depression, were compliant with visits, medication, and follow-up with
providers better than those who were not followed by care management (Palmer,
Vorderstrasse, Weil, Colford, & Dolan-Soto, 2015).
Care coordination was established in the 1990’s as a model used in several
settings, such as health maintenance organizations (HMO’s), and the Centers for
Medicare & Medicaid (Craig, Eby, & Whittington, 2011). Care coordination is essential
to providing quality care for individuals with complex medication regimens, medical
histories, and chronic disease. Plus it is effective for medical and cost outcomes
(American Nurses Association, 2012). Nursing has been integral in providing evidence
of the effectiveness of care coordination programs, such as care transitions to reduce
rehospitalization , and effective coping to manage social issues of homelessness or food
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insecurities (Coleman, Parry, Chalmers, & Min, 2006; Craig et al., 2011). Regarding
mental health care coordination, studies have shown that telephone contacts to follow up
with patients, increase adherence to medication and follow-up appointments (Dietrich et
al., 2004; Oxman, Dietrich, Williams, & Kroenke, 2002).
Currently, the Centers for Medicare & Medicaid have a funded project to
implement care coordination in care transitions of behavioral health to evaluate
rehospitalization because of depression (Gold & Becker, 2015). A report published since
this announcement, documents that those patients hospitalized for serious mental illness
who participated in the care transitions program, had better follow through rates with
their primary care providers than their mental health providers after hospitalization
(Domino et al., 2016). This Domino et al. (2016) report indicates a close tie to primary
care, and deficiencies in communication with specialty providers.
A comparison of care providers may be helpful to identifing interventions to care
for patients with depression. Care coordination programs have been supported by the
American Nurses Association and a white paper describes the pivotal, and important role
that nursing makes in this program (American Nurses Association, 2012). Care
coordination has shown improvements for patient’s quality of care, ability to decrease
costs, and improve survival rates. Yet, in a literature search, no studies were identified
that compared care coordination with primary care or psychiatry providers.
Depression and quality of life
A search for the term “depression” and “quality of life” on EBSCOhost with all
databases chosen, yielded 54,405 articles. Limiting it to peer-reviewed scholarly articles,
full articles available and reducing the years from unlimited to the last three years, the
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result were 15, 754. When the terms “pharmacogenetics” was added, two articles were
returned which were not supportive to this dissertation. When the same search of the
three terms was conducted in PubMed, 13 articles were returned, three were disregarded
because they were duplicates. From these articles bibliographies, and bibliographies of
other identified articles, the following review included 10 articles.
Quality of life includes three main components, physical functioning, social
functioning, and emotional functioning (Ware, Kosinski, & Keller, 1996; Ware &
Sherbourne, 1992a). It is well established that a poor depressive prognosis is associated
with poor quality of life (Bonicatto et al., 2001). In a study of depressed persons, it was
reported that those who were depressed reported a forty percent impairment in quality of
life when compared to those who are not depressed (Ishak et al., 2013). Factors
significantly contributing to decreases in quality of life in the depressed population may
be associated to depressive symptomology, disability, and age (Ishak et al., 2013).
Depression has an impact on not only mental quality of life but physical
functioning, perceived bodily pain and a person’s feelings of general wellness (Saarijarvi
et al., 2002). The SF-36 evaluates eight domains that make up overall quality of life.
These include; physical functioning (PF), physical limitations because of health
problems (RP), physical, body pain (BP), general perceptions regarding health (GH),
vitality (VT), social functioning (SF), limitations due to social or emotional problems
(SE), and mental health (MH) (McHorney, Ware, & Raczek, 1993).
Bonicatto et al. (2001) reported poorer quality of life in persons with depression
than those with or without chronic conditions, which indicates the extent of the impact
depression may have on health outcomes. Similar results were found in an elderly
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population noting that quality of life in depressed persons was at least as debilitating as a
chronic physical condition (Doraiswamy et al., 2002). Additionally, as age increases,
physical quality of life decreased. Interestingly, the elderly tended to have higher scores
overall on the quality of life measure indicating that with age people are more content
overall (Doraiswamy et al., 2002). Understanding the impact of physical health to mental
health can give a more impactful view of depression and its treatments (Ishak et al.,
2013). Not all studies report positive outcomes for those with improvement in
depression. One study reported that only fifty percent of patients who were in remission
for depression, improved quality of life scores (IsHak et al., 2015).
Physical quality of life has been recently evaluated in bipolar participants of the
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study to
examine the relationship of physical quality of life and bipolar symptoms. The analysis
revealed that Role physical and General Health scores within the Short Form 36 survey
were related to and predicted worsening depression. Also, those who reported fewer
depressive symptoms had fewer physical limitations (Bernstein et al., 2016). The
impairment in quality of life for persons with depression and the additional impact on
physical health indicates a need to understand physical symptoms associated with
depression in addition to quality of life (Ishak et al., 2013). Having chronic conditions
could explain why those with remission of depression continue to have decreased quality
of life scores (Alonso et al., 2004).
The literature review reveals that more research is needed in the use and
effectiveness of a locally developed multi-gene assessment to guide provider
pharmacotherapy prescribing. Also, when considering other published studies that
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include a comprehensive pharmacogenetic report related to psychotropic medications, it
is interesting to note that quality of life has not been addressed (Altar et al., 2015{HallFlavin, 2013 #242). The STAR*D literature indicates the need for quality of life
assessment to more fully understand patients and their depression symptoms (Trivedi et
al., 2006).
Theoretical Framework
The theoretical framework for this new study had no changes from the previous
study and is as described in chapter one and two.
Nursing theory
The nursing theory used was Orem’s Theory of Self-care. This is unchanged
from Chapter one and two. The new model appears below in Figure 5. This illustrates
changes in depression severity, depression symptoms and quality of life without regard
for provider type. However, the awareness of having pharmacogenetic care, may impact
a patient outcome positively. Some authors have indicated that this is a placebo effect
(Haga, Warner, & O'Daniel, 2009)
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Awareness of current medication regime

Awareness of medications based on genetics
Patient after Start of
Pharmacogenetic care
(T1 to T2) and
Pharmacogenetic Care
(T2 to T3)

Patients before
Pharmacogenetic Care:
Time 1

SELFCARE

SELF-CARE
AGENCY

SELF-CARE
REQUISITES

Person (s) in self-care deficit

SELFCARE

SELF-CARE
AGENCY

SELF-CARE
REQUISITES

Person(s) in Life Situations Managing
and Attending to Self

Quality of Life (SF-36)

Quality of Life (SF-36)

Depression (PHQ-9)

Depression (PHQ-9)

Depression symptoms
(QIDS-SR16)

Depression Symptoms
(QIDS-SR16)

Figure 5. Depression severity (PHQ9), depression symptoms (QIDS-SR16), and quality of
life (SF-36), as they are associated to Self-care deficit.

Study significance
In consideration of providers, nurse prescribers, and other professions working
with patients, opening communication between the provider and patient because of
pharmacogenetic testing may increase patient’s quality of life, and decrease depression
severity and symptoms. Furthermore, increases in quality of life may promote patient’s
active participation in self-care behaviors, decrease missed clinic visits and promote the
intentional and appropriate use of resources. Few differences have been identified
between primary care and psychiatry in studies to date. However, indications that
managed care may be beneficial to depression outcomes can be evaluated through a
comparison of care coordination to primary care and psychiatry. Current literature was
not identified that show evidence of what differences might be found between these
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populations. The American Nurses Association (2012) provides primary evidence to the
impact that nursing can make on the outcomes of patients who are participating in care
coordination. Nursing is poised for providing interventions which may be helpful to care
coordination participants with depression.
Methods
The purpose of this dissertation study was to evaluate by provider types of care
coordination, primary care and psychiatry, the change of depression severity (PHQ-9),
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a
population of patients diagnosed with MDD or DDNOS after having had
pharmacogenetic testing. The methods section will discuss study design, population,
study data collection, instruments used, and statistical analysis.
Study Design
This study was an analysis of data from three similar studies evaluating MDD and
DD-NOS. The data from these three studies were combined. All of the studies utilized a
prospective, repeated-measures design and two of the studies were randomized
prospective repeated-measure designs.
Sample and Setting
This study was conducted in collaboration with a large health care system, clinics,
and hospitals in the upper Midwestern United States. The health system covers over
70,000 members in three states, and there are over 300 facilities within the health system.
This study focused on participants in three studies of pharmacogenetics in patients who
had a diagnosis of depression and who had completed three visits. The three key visits
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analyzed included a baseline visit (T1), a visit at pharmacogenetics reporting (T2), and a
visit after pharmacogenetic report (PGXr) has been given to providers (T3). If the
subject were in a study that had randomized pharmacogenetics results given to the
provider at 12 weeks, the same data collection points would be utilized. However, there
would be different time intervals between data collection points. For example, a patient
who is randomized to “twelve-week reporting”, will receive a pharmacogenetics report
eight weeks after the patient who is randomized to “four-week reporting” (Table 4)
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Table 5
Three study randomizations
Primary care and Specialists care: RANDOMIZED TO 4 WEEKS
weeks
Time point evaluated
Visit Number
PHQ9
QIDS-SR16
SF-36

0
*T1
V1
x
x
x

4
8
*T2 *T3
V2 V3
x
x
x
x
x
x

PGXr (randomized to 4 or 12 weeks)

x

PGXr (randomized to 4 or 12 weeks)
Care Coordination study: had no randomization
weeks
0
Time point evaluated
*T1
Visit Number
V1
PHQ9
x
QIDS-SR16
x
SF-36
x
PGXr
*Time points evaluated for this study.

x

12

16

18

V4
x
x
x

V5
x
x
x

V6
x
x
x

x
**data not utilized
for this analysis
Primary care and Specialists care: RANDOMIZED TO 12 WEEKS
weeks
0
4
8
12
16
18
Time point evaluated
*T1
*T2 *T3
Visit Number
V1
V2 V3
V4
V5
V6
PHQ9
x
x
x
x
x
x
QIDS-SR16
x
x
x
x
x
x
SF-36
x
x
x
x
x
x

4
8
*T2 *T3
V2 V3
x
x
x
x
x
x
x

x
12

16

18

V4
x
x
x

V5
x
x
x

V6
x
x
x

Population
The sample population included participants in three studies of depression and the
criteria for this analysis included the following:
Inclusion criteria
1. The participant had a diagnosis of MDD or DDNOS.
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2. The participant had completed informed consent for the study in which they
were enrolled.
3. All participants in the study were evaluated regardless of how many visits
they had completed.
4. The provider managing the patient’s depression (primary care or specialist)
consented to the patient’s participation in the study.
5. Participants were 18 years old or older, males or females.
6. Participants were taking, or the provider planned on starting, an antidepressant
medication to be included in the study.
7. Participants who had a history of substance abuse, other than nicotine, had to
be stable in the opinion of the principal investigator and provider.
8. Participants had a life span expectancy of a year or longer.
9. Subjects must have been able to read and write in English.
Exclusion criteria. All patients met the exclusion criteria to participate in the dissertation
research.
1. Participants were not pregnant or breastfeeding mothers.
2. Participants were not younger than 18 years old.
3. Participants did not have a primary diagnosis of Dementia, bulimia, or anorexia
nervosa disorder diagnosis.
4. Participants who had a previous pharmacogenetic evaluation were excluded.
5. Participants who had disorders affecting drug absorption (i.e., Crohn’s Disease
or Colitis, significant surgical procedures affecting medication or food
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absorption, or conditions as identified by the principal investigator to interfere
with medication absorption).
Recruitment. Recruitment was described in the “care coordination” dissertation
chapters’ methods section. Recruitment for those in the ‘primary care provider’ or the
‘specialists (psychiatry) studies occurred through provider referral to the study staff of
those studies. Primary care participants were recruited from various clinics and hospitals
throughout the health system, and all study visits were completed over the phone.
Questionnaires were mailed to participants and follow-up phone calls made as needed.
The specialists (psychiatry) study participants were referred by their psychiatrist and
were seen in the psychiatrist’s office. All questionnaires for these patients were
completed in person at the psychiatry office.
Study Schedule. For this study regardless of randomization, the study visits
assessments included the baseline, the visit at which the PGXr was given to the provider,
and one month after the pharmacogenetics report was received (Table 3 and 4)
Data Collection
Instruments
Patient Health Questionnaire-9 (PHQ9). The PHQ9 is a 9-item, self-report
measure of depression severity, scored from zero to 27. Each of the nine questions have
four answer options (0-3) defining the severity and, or frequency of symptoms over the
past two weeks; zero denotes ‘no symptoms at all’. A score of 1 represents symptoms are
experienced ‘several days’, and a 2 indicates that symptoms are experienced ‘more than
half the days’. The highest score, 3, signifies ‘nearly every day’ symptoms are
experienced. The instrument evaluates the previous two weeks. PHQ9 scores ranging
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from 0-4, were minimal depression, 5-9 indicate mild depression, 10-14 represent
moderate depression, 15-19 designate moderately severe depression and more than 20
designates severe depression (Kroenke, Spitzer, & Williams, 2001; Manea, Gilbody, &
McMillan, 2011).
When the PHQ9 was evaluated and compared to independent physician diagnosis,
it was found to be accurate at 85%, have 90% specificity, with a sensitivity of 90%
(Spitzer, Kroenke, & Williams, 1999). The PHQ9 has a reported Cronbach’s alpha of
0.85 indicating good internal reliability, and Spitzer et al. (1999) reported criterion
validity based on the concurrence of diagnoses indicated by individual providers
compared to the PHQ9. Construct validity was strong when SF-20 was compared to
PHQ9 measurement indicated that as PHQ9 scores rise, patient’s functional status
decreases on the SF-20.
Quick Inventory of Depressive Symptomology-Self Report 16 (QIDS-SR16).
The QIDS-SR 16 was developed from a 30 Item Inventory of Depressive Symptomology
(IDS30) to decrease the length and develop a self-report scale and clinician’s rating scale
(Rush, Gullion, Basco, Jarrett, & Trivedi, 1996; Rush et al., 2003). This scale was
evaluated against the Hamilton Depression Scale (HAMD24) which has (Cronbach’s
alpha = 0.88) high internal consistency (Rush et al., 2003). The internal consistency of
the QIDS-SR16 was also found to be high (Cronbach’s alpha = 0.92), and total scores are
predictive of HAMD17 scores by multiplying 1.3 times the total QIDS-SR16.
Additionally, high relative validity has been established with other instruments including
the HAMd24, HAMD17, QIDS30, and MADRS (Carmody et al., 2006). A comparative
table is available for HAMD24, HAMD17, and QIDS30 (Rush et al., 2003).
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The QIDS-SR16 is a self-report tool which evaluates nine domains including a)
sad mood; b) concentration; c) self-criticism; d) suicidal ideation; e) interest; f)
energy/fatigue g) sleep changes including initiation of sleep, middle and late insomnia or
hypersomnia; h) increased or decreased appetite/weight; i) psychomotor
agitation/retardation. Each domain has two to three questions associated with it for a
total of sixteen questions. Each of the nine items is scored with a value given from 0-3
for each answer. The highest item score within a domain is chosen as the final score for
that domain. The total scores for the nine domains may range from zero to twenty-seven.
Twenty-seven reflects the most severe symptoms related to depression. Mild depression
is scores of six to ten, 11-15 is moderate, 16-20 is severe and more than 21 is very severe
depression (Rush et al., 1996; Rush et al., 2003; Trivedi et al., 2004).
Short Form 36 (SF-36) Health Survey. The Short Form-36 (SF-36) Health
Survey for measuring quality of life, was developed to understand health outcomes in
population health, clinical health initiatives, and research in many different disease states
that include pain, cardiovascular disease, cancer and psychiatric diagnoses as some of the
most prolific uses. It has been widely published with over 4,000 publications using this
instrument to measure health outcomes (Turner-Bowker, Bartley, & Ware, 2002).
The quality of life measure, the SF-36 is a 36 item self-report instrument, using
both five-point and 3 point Likert scales. The five-point scale goes from a score of zero
to five, zero being severe symptoms and five being no symptoms. The three-point scale
is used, for example, when asked about physical limitations and zero indicates ‘yes,
limited a lot’ while three indicates, ‘not limited.' All subscales are scored from zero,
which is severe symptoms to 100 which is no symptoms. The subscales are combined
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and averaged to create a ‘physical composite score’ and a ‘mental composite score’. A
zero represents poor quality of life, to 100 which is high quality of life. The higher the
score, the better quality of life is observed by participants. McHorney et al. (1993); Ware
et al. (1996); Ware and Sherbourne (1992a) explain the eight domains of health
including; ‘physical functioning’ (PF), physical limitations because of health problems‘role physical’ (RP), physical, ‘body pain’ (BP), general perceptions regarding health‘general health’ (GH), ‘vitality’ (VT), ‘social functioning’ (SF), limitations due to social
or emotional problems ‘role emotional’ (RE), and ‘mental health’(MH). The ‘mental
composite score’ (MCS) and the ‘physical composite score’ (PCS) are averages of four
related subscales. The MCS includes PF, RP, BP, and GH. The PCS includes VT, SF,
RE, and MH. The two scores which are commonly used are the PCS and MCS (Ware &
Sherbourne, 1992b). Each domain and meanings of each domain and what they represent
are presented (Table 6). Frendl and Ware (2014) evaluated pharmaceutical clinical
studies that utilized the SF-36 and noted that there were significant changes in scores in
several disease states, the top being rheumatoid arthritis, and psoriasis. Depression was
also noted to have good responses for changes in the SF-36 after beginning medication,
which confirms the usefulness of the SF-36 in clinical trials utilizing drug therapy (Frendl
& Ware, 2014).
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Table 6
SF36 subscales
Physical Composite
Score

physical functioning

role-physical
Bodily pain

General Health
Mental Composite
Score
Vitality

Low Scores (0 - 50)

High Scores (> 50)

Unable to complete
activities of daily
living
Physical health
interferes with work
or job activities
Severe pain
Has the belief that
health will become
worse

Completes activities
of daily living
without limitations
Physical health does
not interfere with
work activities
mild to no pain

Low energy levels

Has energy and pep
There are no social
life limitations
because of either
emotional or physical
problems
No work or job
interferences because
of emotional
problems.
Feels happy and
relaxed most of the
time.

Social Function

physical or emotional
problems interfere
with social life

Role-emotional

Emotional problems
interfere with work or
job activities

Anxiety or sadness
Mental Health
most of the time
Ware and Sherbourne (1992a, p. 475)

Has the belief that
health will improve

Number of chronic conditions and mental health conditions. The number of
chronic conditions and mental health conditions was a tally of diagnoses, one number for
a chronic condition and one number for mental health conditions as listed in the patient’s
medical record and associated with an ICD-9 or ICD-10 code.
Demographic Information. Age, gender, type of medical insurance, marital status, and
employment status were collected.
Statistical Analysis

74
Sample size estimate. Sample size was based on recruited patients up until
January 2016 when the study was stopped. Original sample size estimates were 100 per
study based on the G*POWER sample size calculator. The statistical plan is represented
below (Table 7).
Table 7
Statistical plan
Hypothesi
Variable
s
PHQ9 1
Dependent

Type of
Variable
discrete variable
(nominal)

2

QIDS-SR
Dependent

continuous/inter
val/ratio

QIDS-SR at T1-3

3

QOL-Mental
Health
dependent

continuous/inter
val/ratio

QOL-MH at T1,
T2, T3

4

QOL physical
continuous/inter
health
val/ratio
dependent

5

Genetics

Comparison

Statistical Test

PHQ9 at T1, T2,
T3

mixed linear
models

QOL-PH at T1,
T2, T3

mixed linear
models
mixed linear
models/
JonckheereTerpstra
mixed linear
models/Jonckh
eere-Terpstra

descriptive
statistics
(frequencies)

T1 = Time 1, T2 = Time 2, T3 = Time 3
Data analysis. Data was entered into SPSS® v.22, and double checked by two
additional staff persons. A master file copy was saved, and password protected as backup
for the working file. A working file copy was made to conduct the analysis.
Additionally, initial checks for outliers and frequency distributions, boxplots, histograms
and descriptive statistics were conducted. Data analysis included the mixed linear model.
This model is helpful to use with data such as is presented here, which has missing
variables, and inconsistent group sizes (Field, 2013).
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CHAPTER 4
Results
The purpose of this dissertation study was to evaluate by provider types of care
coordination, primary care and psychiatry, the change of depression severity (PHQ-9),
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a
population of patients diagnosed with MDD or DDNOS after having had
pharmacogenetic testing. This chapter describes the data collection, cleaning, and
analysis methods and results for each question.
Review of Data Collection Procedure
Summary of study procedures and study sample. Data was collected from
three ongoing studies of pharmacogenetics in depression. All patients had a diagnosis of
Major Depressive Disorder (MDD), or Depressive Disorder- Not otherwise specified
(DDNOS). All participants completed the same questionnaires including the PHQ9 to
measure depression severity, the QIDS-SR to measure depression symptoms, and the
SF36 to measure quality of life.
Each study sought to enroll 100 volunteers per provider type. At the time of this
analysis, 100 participants had not yet been achieved for each study. Data collected
through February 6, 2016, was combined to complete this analysis and included
populations with the differing provider types of care coordination (n = 26), primary care
(n = 38), and psychiatry (n = 54). All participants were included in the analysis who had
signed informed consent for their study regardless of how many visits the participants
had completed. Two of the studies, primary care and psychiatry, were randomized
studies. The study visits were standardized, so that regardless of randomization, the same
time points were evaluated. Evaluation of a baseline visit, the visit which the participant
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received their pharmacogenetics report (PGXr) and one visit four weeks after receipt of
the PGXr were collected for data analysis.
Data collection challenges included missed visits, due to patient non-compliance
and missed visits related to the visit number which the participant was currently
completing at the time the study closed enrollment. Some participants were newly
enrolled and only finished one visit while others had completed the entire study at the
date of the data analysis.
Questionnaire data was manually entered into a Microsoft Excel spreadsheet for
each study. After manual entry, data was double-checked by an independent researcher.
Data was source verified, de-identified and cleaned for analysis. All data was password
protected, and analysis was completed in SPSS® v. 22.
Statistical Methods. Descriptive statistics were implemented for data analysis of
the populations. These included frequency, means (M), standard deviations (SD),
medians, and sample size counts. This information was used to understand missing
values, and distributions of the data. T-tests were conducted for comparison of groups;
Bonferroni corrections were made when multiple t-tests were completed.
A mixed linear model was used to analyze the repeated measures of depression
severity (PHQ9), depression symptoms (QIDS-SR16), and quality of life (SF36). Mixed
linear model was chosen over ANOVA for repeated measures because of the number of
missing values, and missed visits (Bernstein et al., 2010). Mixed linear models are more
robust in analyzes when there are missed visits, which may interfere with sample size
(Hardin & Hilbe, 2012; Heritier, 2009). Mixed linear models provide information
regarding the data in a multilevel evaluation of repeated measures such as are represented

77
in this study. This model provided information regarding between and within group
effects. Schwarz’s Bayesian Criterion was evaluated for p values of each model selected.
The validity of each model utilized having a p-value < .05, was tested against variations
of the final statistical model. To understand detailed trends and rank between groups and
time periods for the quality of life criteria (SF36), the Jonckheere-Terpstra trend statistic,
a non-parametric test, was used for the concepts included in the ‘mental composite
scores’ (MCS) and ‘physical composite scores’ (Jonckheere, 1954) for more information
regarding the subscale concepts, refer to the table (Table 5).
Internal reliability for questionnaires
A Cronbach’s alpha was calculated for each questionnaire used for this study and
showed good reliability as > 0.70 for all questionnaires used. The PHQ9’s Cronbach’s
alpha was .88, which was slightly higher than the reported .85 of previous studies. The
QIDS Cronbach’s alpha was .76, which was lower than previous reports of .88 -. 92. The
SF-36 has two measures, physical composite score (PCS) and mental composite scores
(MCS), which were Cronbach’s alpha was .97 and .89 respectively. The SF36 subscale
Cronbach’s alpha for both primary scores of MCS, and PCS ranged from .79 to .94. The
SF-36 internal reliability measures were similar to previously reported Cronbach’s
alphas.
Demographic results
Sample Demographic results. The sample population participated in three
studies conducted in the upper Midwest. The studies included patients who were referred
by their providers including primary care, and psychiatric providers along with care
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coordination referrals. Tabular demographic results are represented (Table 8) and clinical
demographics are also presented (Table 9).
Table 8

Demographic distribution

Gender
N = 124

Male

Female
Caucasian
Ethnicity
a
N = 117
Unknown
American
Indian
Employment
Employed
Status
Unemployed
N = 124
Retired
Disabled
Unknown
Marital Status
Single
a
N = 117
Married
Divorced
Separated
Widowed
Insurance Type
Private
N = 124
Self-pay
Medicaid
Smoking status
Non-smoker
b
N = 121
Current
smoker
Former
smoker
Unknown
a. Missing data (n = 7) N = 124.
b. Missing data (n = 3) N = 124.

n=

%

31

24%

93
115
1

73%
90%
1%

1

1%

46
7
6
10
55
39
59
16
0
3
83
4
37
74

37%
6%
5%
7%
43%
32%
48%
13%
0%
2%
65%
2%
30%
61%

17

14%

19

16%

11

9%

The total sample size was N = 124, with ages ranging from 19 to 84 years old (M
= 45, SD = 14.66). The overall sample was Caucasian (90.3%) and female (73.4%). In
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addition, the majority of the population was employed (37.1%) with private insurance
(65.3%), and fewer participants were unemployed (4.6%), retired (4.8%) or disabled
(7.3%). Similarly, fewer participants had Medicaid (29.8%) or were self-pay (2.4%).
Most participants were married (47.6%) followed by less who were single (31.5%).
There was a wide range (0-17) of number of chronic conditions.
Table 9
Total Sample Descriptive Statistics
N
Minimum Maximum
120
19
84

Age
Number of chronic
illnesses
Number of mental
health diagnoses
Number of medications

M
45.69

SD
14.67

118

0.00

17.00

4.37

3.90

118

1.00

6.00

2.08

1.18

115

0

37

10.64

7.17

Demographics based on provider type. The demographics by provider
included, care coordination (n = 24), primary care (n = 41), and psychiatry (n = 54). The
demographics information gathered during the study included: a) age b) gender c)
primary health insurance d) marital status e) ethnicity, d) employment, e) number of
chronic health conditions f) number of mental health conditions. Primary health
insurance was categorized as self-pay, Medicaid, or private insurance. Employment was
classified as employed, unemployed, disabled, retired or unknown. Marital status was
classified as single, married, divorced, separated, or widowed. Clinical demographic
descriptive statistics were conducted on these data (Table 9).
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Table 10
Demographics by provider type
Care
Coordination
n = 26
%
73.1
26.9
92.3
3.8

Primary
Care
n = 41
%
80.5
19.5
87.8
12.2

n = 54
%
72.2
27.8
96.3
3.7

3.8

0.0

0.0

Private

30.8

75.6

77.8

Self-pay
Medicaid

3.8
65.4

0.0
24.4

3.7
18.5

Employed

38.5

26.8

46.3

Unemployed
Disabled
Unknown
Retired

3.8
23.1
34.6
0.0

9.8
0.0
61.0
2.4

3.7
5.6
35.2
9.3

Single

38.5

36.6

25.9

Married
Divorced
Widowed

42.3
19.2
0.0

51.2
4.9
2.4

46.3
14.8
3.7

Sample Characteristic
Sample size
Gender
Ethnicity

Insurance
Type

Employment
Status

Marital
Status

Female
Male
Caucasian
Unknown
Native
American

Psychiatry
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Table 11
Clinical demographics by provider type
Care
coordination
M (SD)
50.38 (11.19)

Primary Care

Psychiatry

M (SD)
44.10 (15.01)

M (SD)
44.61(15.62)

7 (3.5)

3.52 (4.17)

3.7 (3.32)

Number of mental
health diagnoses

2.15 (1.54)

2.12 (1.07)

2.0 (1.07)

Number of
Medications

15.04 (6.83)

8.62 (6.22)

9.88 (7.16)

Age
Number of chronic
conditions

n = 4 missing data for age, n = 6 missing data for number of chronic illnesses and number
of mental health diagnoses, n = 9 missing for number of medications. N = 124
Age. Age was compared for three groups, care coordination, primary care and
psychiatry. Groups were similar p = 0.149, at a significance level of p = .05. The mean
age among groups, were care coordination (M = 50.38, SD = 11.19), psychiatry (M =
44.61, SD = 15.62) and primary care (M = 44.10, SD = 15.01).
Gender. The total sample for all groups included 32 males and 94 females. The
proportions in gender between groups were similar; care Coordination (73.1%), primary
care (80.5%) and psychiatry (72.2%).
Insurance type. Private insurance was the primary insurance type for both
primary care and psychiatry (n = 31; n = 42). Medicaid was the primary insurance type
for care coordination with (n = 17).
Marital status. This study’s total population included the largest percent who
were married (47.6%) over those who were single (31.5%). Similarly, Table 10 shows
that each group has a high number of married and single participants. Care coordination,
primary care, and psychiatry all had the high percentages of people whose status was
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married, 42.3%, 51.2%, 46.3% respectively. Care coordination had the highest
percentage of divorced and single participants 19.2% and 38.5% respectively.
Employment. Primary care, care coordination and psychiatry groups had the
following rates of employment, respectively from 26.8%, 38.5%, to 46.3%. Care
coordination had the highest percentage of disabled participants (23.1%), and psychiatry
had the highest percentage of retired participants, 9.3%.
Number of chronic conditions. There was a difference (p < 0.001) in chronic
physical conditions between care coordination, (M = 7.0, SD = 3.5), primary care (M =
3.52, SD = 4.169) and psychiatry (M = 3.7, SD = 3.32).
Number of mental health diagnoses. There was no difference among groups for
the number of mental health diagnoses (p = 0.801).
Number of medications. Care coordination patients were prescribed more
medications than primary care (p = .001), and psychiatry groups (p = .006). There was
no difference between primary care and psychiatry groups (p = 1.00).
Analysis of group for depression severity (PHQ-9)
Table 12
PHQ mean scores all patients

Visit
1.00
2.00
3.00
Total

n
120
99
90
309

M
14.6000
11.7879
10.2444
12.4304

SD
5.50080
5.78223
6.26263
6.08483

95% Confidence Interval for
Mean
Upper
Lower Bound
Bound
13.6057
15.5943
10.6346
12.9411
8.9328
11.5561
11.7493
13.1115

The mean depression severity scores decreased over time F (2, 303) = 15.3l, p =
.001. There was a decrease in score from visit one (M = 14.6, SD = 5.5) to visit two (M =
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11.78, SD = 5.7), with a mean decrease M = -2.8, 95% CI [-4.7, -.91], which was
statistically significant (p = .001). Table 11 shows means and standard deviations for
each visit. There was not a significant decrease from visit two (M = 11.79, SD = 5.8) to
visit three (M = 10.2, SD = 6.2) with a mean decrease M = -1.54, 95% CI [-3.6, .50],
which was not statistically significant (p = .21). The mean decrease from visit one to
visit three was significant, M = -4.36, 95% CI [-6.31, -2.40], p < .05.
Analysis of group for depression symptoms (QIDS)
Table 13
Mean scores for all participants QIDS
95% Confidence
Interval for Mean
Visit
1
2
3
Total

N
121
99
92
312.00

M
13.10
12.14
9.62
11.77

SD
4.52
6.98
5.15
5.75

Lower
Bound
12.28
10.75
8.55
11.13

Upper
Bound
13.91
13.53
10.69
12.41

The mean depression symptom scores decreased over time F (2, 309) = 10.46, p <
.001. There was a decrease in mean score from visit one to visit two (Table 13).
However, this did not represent a significant change, as represented by a mean decrease
M = -.96, 95% CI [-2.8, .87], p = .62. There was a decrease from visit two to visit three
with a mean decrease M = -2.5, 95% CI [-4.5, -.57], p = .01). The mean decrease from
visit one to visit three was significant, M = -3.5, 95% CI [-5.3, -1.6], p = < .001.
Analysis of group for QOL-physical composite scores
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Table 14
SF-36 Mean physical quality of life scores by visit-PCS
95% Confidence Interval
for Mean
Visit
1
2
3
Total

N
119
90
92
301

M
43.96
45.48
45.75
44.96

SD
12.36
12.77
12.20
12.42

Lower Bound
41.72
42.81
43.22
43.55

Upper
Bound
46.20
48.16
48.27
46.37

There was not a change in physical quality of life F (2, 298) = .648, p = .52. The
means are represented at each visit (Table 12), and the change in means between visits
(Table 14) are also represented.
Table 15
SF-36 multiple comparisons of physical composite score by
visit
95% Confidence
Interval
M (mean
Upper
(I) VISIT
difference)
p
Lower Bound Bound
2
-1.52
1.00
-5.71
2.66
1
3
-1.79
0.91
-5.94
2.37
1
1.52
1.00
-2.66
5.71
2
3
-0.26
1.00
-4.70
4.18
1
1.79
1.73
0.91 -2.37
3
2
0.26
1.84
1.00 -4.18
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Analysis of group for QOL-mental composite scores
Table 16
SF-36 mean scores by visit- Mental composite score
95% Confidence Interval
for Mean
Upper
N
M
SD
Lower Bound
Bound
1
119
29.97
11.21
27.93
32.00
2
90
35.23
13.01
32.51
37.96
3
92
36.97
12.15
34.46
39.49
Total
301
33.68
12.41
32.28
35.09

There was an increase in quality of mental composite scores, F (2,298) = 9.8, p <
.001. (Table 16). A pairwise comparison indicates that there was an increase from visit
one to visit two, M = 5.3, 95% CI [1.21, 9.3], p < .01 and between visits one and three, M
= 7, 95% CI [ 2.97, 11.3], p < .001. However, there was not a change between visit two
and visit three, M = 1.74, 95% CI [-2.56, 6.04], p = .993.
Research questions
1.

Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in depression severity (PHQ9) over time (T1-T3)
based on the type of provider?

The statistical model for the PHQ9 included time and provider type as main effects
and time and provider interactions (p < .05). The interaction of provider type and time
was significant for depression severity, F (2, 102.81) = 3.84, p = .024. Pairwise
comparisons indicate that care coordination patients had less severe depression severity, b
= -2.501, t = -7.718, p < .001, than primary care and psychiatry patients. In contrast,
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there was no difference between PHQ9 scores for primary care and psychiatry in
depression severity b = .499, t = .89, p = .373.
a. Hypothesis 1: Depression severity scores (PHQ9) among patients who
receive care coordination will decrease over time.
This study found that PHQ9 mean scores (SD) decreased with each visit from
visit one to visit three respectively, M = 10.52, SD = 6.85; M = 10.18, SD = 7.60; M =
8.11, SD = 6.34. However, this did not represent improvement, t = 1.195, p = .24. This
hypothesis was not supported. Depression severity was represented as changes in
patient’s depression severity of levels > 9 to levels < 9, indicating clinical improvements
(Table 17)
Table 17

PHQ scores
Overall Group n = 121
Number of participants
Percent of participants
Care Coordination n = 26
Number of participants
Percent of participants
Primary Care n = 41
Number of participants
Percent of participants
Psychiatry n = 54
Number of participants
Percent of participants

PHQ-9 (< 8)
Low Depression
Severity
Visit 1 Visit 2 Visit 3

PHQ-9 (≥ 9)
High Depression
severity
Visit 1 Visit 2 Visit 3

44
36.36

80
66.12

94
77.69

77
63.64

41
33.88

27
22.31

16
64.54

22
84.62

23
88.46

10
38.46

4
15.38

3
11.54

12
29.27

26
63.41

33
80.49

29
70.73

15
36.59

8
19.51

16
29.63

32
59.26

38
70.37

38
70.37

22
40.74

16
29.63

b. Hypothesis 2: Depression severity scores (PHQ9) among patients who
receive care by a Primary care provider will decrease over time.
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PHQ9 mean scores decreased with each visit from visit one to visit three, M =
16.0, SD = 4.955; M = 13.73, SD = 5.11; M = 12.0, SD = 5.98. These means indicate a
decrease in depression, t = 2.874, p = .006. Twenty-one participants (51%) who were
being managed by primary care providers reduced their depression severity scores from
being greater than 9 (moderate to severe) to less than 9 indicating a mild depression
status (Table 16). This hypothesis is supported.
c. Hypothesis 3: Depression severity scores (PHQ9) among patients who
receive care by a Psychiatrist will decrease over time.
PHQ9 mean scores decreased with each visit from visit one to visit three, M = 15.42,
SD = 4.25; M = 11.16, SD = 5.33; M = 10.2, SD = 6.22. This indicates a decrease in
depression severity from visit 1 to visit 3, t = 4.95, p < .000. Twenty-two participants
(41%), reduced their depression severity category by moving from having a score greater
than nine at visit one to having a score less than nine at visit three. This hypothesis is
accepted.
Table 18
QIDS severity groups
Overall Group
Number of participants
Percent of participants
Care Coordination
Number of participants
Percent of participants
Primary Care
Number of participants
Percent of participants
Psychiatry
Number of participants
Percent of participants

QIDS-SR (<10)
Fewer symptoms
Visit 1
Visit 2

QIDS-SR (≥11)
More symptoms
Visit 1
Visit 2

Visit 3

48
39.67

73
60.33

92
76.03

73
60.33

48
39.67

29
23.97

16
64.54

19
73.08

22
84.62

10
38.46

7
26.92

4
15.38

11
26.83

31
75.61

30
73.17

30
73.17

10
24.39

11
26.83

21
38.89

23
42.59

40
74.07

33
61.11

31
57.41

14
25.93

Visit 3
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2. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in depression symptoms (QIDS-SR16) over time
(T1-T3) based on provider type?
Table 19
Type III Tests of Fixed Effects QIDS
Numerator Denominator
Source
df
df
F
Provider
118.932 6.929
2
Visit
98.492 34.829
1
Provider * Visit
2
97.521 3.055
a. Dependent Variable: QIDS.

p
.001
.000
.052

The statistical model included interaction and main effects of provider type and visit
for depression symptoms (QIDS) at the level of p < .05. There was no interaction found
between provider type and change over time for depression symptoms, F (2, 97.52) =
3.05, p = .052. There were main effects of visit and provider (Table 18). The number of
participants who moved from high levels of symptoms (QIDS >11) to low levels of
symptoms (QIDS <11) are presented above (Table 17). Clinically, this indicates that
36% of patient’s symptoms improved from visit one to visit three (Table 17).
a. Hypothesis 1: Depression symptom scores (QIDS-SR16) will decrease
over time (T1-3) among patients who receive care coordination.
For care coordination the mean scores declined from M = 10.5, SD = 4.14 at visit
one to M = 9.0, SD = 3.56 at visit 3. However, visit two increased to M = 11.6, SD =
5.2. Overall, this did not represent a decrease in symptoms, t = 1.19, df = 15, p = .25.
The hypothesis was not supported. Clinically this represents a change from high

89
depression symptoms (QIDS > 11) to low depression symptoms (QIDS <11) for 23% of
patients. This does not support the hypothesis.
b. Hypothesis 2: Depression symptoms scores (QIDS-SR16) will decrease
over time (T1-T3) among patients who receive Primary care services.
Visit one M = 14.8, SD = 4.72, decreased to M = 9.77, SD = 4.63 at visit two and
then increased to M = 11.0, SD = 5.3 at visit three. This represented a decrease in
depression symptoms, t = 2.9, df = 24, p = .007. Clinically this represented a change
from high depression symptoms (QIDS >11) to low depression symptoms (QIDS< 11)
for 46% of patients. This supports the hypothesis.
c. Hypothesis 3: Depression symptoms scores (QIDS-SR16) will decrease
over time (T1-T3) among patients who receive care through psychiatry.
The mean depression symptom scores decreased from visit one to visit three
respectively, M = 13.1, SD = 4.0; M = 13.64, SD = 8.2; M = 9.1, SD = 5.5. This
represents a decline from baseline assessment to visit three, t = 5.8, df = 47, p = .000.
Clinically this represent a change from high depression symptoms (QIDS >11) to low
depression symptoms (QIDS< 11) for 35% of patients. This supports the hypothesis.
3. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in the physical composite score (physical
functioning, role physical, bodily pain, general health) of the SF-36 scale by
provider type?
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Table 20
Estimated Marginal Means for PCS by Provider

Provider
type
Care
Coordination

95% Confidence
Interval
Lower
Upper
Bound
Bound

M

SD

df

37.12

2.28

119.69

32.60

41.64

120.60

42.56

49.64

117.34

44.02

50.20

Primary
46.10
1.79
Care
Psychiatric
47.11
1.56
Care
a. Dependent Variable: PCS.

A one-way ANOVA indicates that care coordination patients had poor physical
quality of life compared to both primary care F (2, 116) = 10.38, p = .000 and psychiatry
patients, F (2, 89) = 4.38, p = .015. There is no difference between primary care and
psychiatry groups, with a mean difference of -1.1, SE = 2.39, p = .646.
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Table 21
SF 36 Quality of life, comparison of visit and provider
Primary Care
Psychiatry
Care Coordination
SF-36
(PC)
(PS)
Visit
(CC)
represented in
represented
Concept
represented in means
means
in means
1
35.02*
64.44
68.35
PCS
No comparisons made, there were no differences found
2
at this visit.
3
29.33*
48.93
51.74
1
39.02*
66.6
64.78
PF
No comparisons made, there were no differences found
2
at this visit.
3
30.64*
50.77
50.11
No comparisons made, there were no differences found
1&2
RP
at this visit.
3
1

BP

2
3
GH

1-3

MCS

1
2&3

VT
SF
RE
MH

35.92*
43.82
52.27
41.46*
62.15
67.08
No comparisons made, there were no differences found
at this visit.
31.69*
47.59
51.63
No comparisons made, there were no differences found
at this visit.
91.96*
49.26
53.24
No comparisons made, there were no differences found
at this visit.

There were no differences in VT, SF, RE at any visit.
1

86.24
54.06
52.22
No comparisons made, there were no differences found
2 &3
at this visit.
*significant difference found.

a. Hypothesis 1: Overall physical composite scores (PCS) of the SF-36 scale will be
highest in psychiatry and primary care, and lowest in care coordination.
A pairwise comparison of the PCS scores per provider group was conducted using
the Jonkheere-Terpstra trend statistic to determine trends over visits and between
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groups. There was a difference found between groups at visit one, T JT = 2,595, z = 3.4, p
= .001, and at visit three T JT = 1,656, z = 2.5, p = .01. There were no differences found
at visit two T JT = 1,425.5, z = 1.662, p = .09. and therefore no pairwise comparisons
were completed (Table 21). This hypothesis was supported.
Table 22
Pairwise comparison QOL PCS
Visit

Pairwise comparison
*CC < PC
1
*CC < PS
PS compared to PC
2
No differences noted
*CC < PC
3
*CC < PS
PS compared to PC
*indicates a difference
CC = Care coordination
PC = Primary care
PS = psychiatry

Statistic
TJT = 763, z = 3.3, p = .000
TJT = 1,036, z = 4, p = .000
TJT = 1,155, z = .522, p = .30
TJT = 1,425.5, z = 1.662, p = .09
TJT = 357, z = 44.4, p = .009
TJT = 618, z = 3.05, p = .001
TJT = 618, z = .412, p = .32

b. Hypothesis 2: When comparing by provider types, physical functioning
scores in the SF-36 scale will be the highest in psychiatry and primary
care and the lowest in care coordination.
Physical function scores were different between provider groups at visit one T JT =
2,743, z = 2.4, p = .02, and visit three T JT = 1,580.5, z = 2.0, p = .045, but not at visit 2,
TJT = 1,419.5, z = 1.4, p = .150. At visit one and visit three, care coordination had poorer
physical functioning quality of life scores, indicating more difficulty with activities of
daily living than primary care, and psychiatry groups (Table 21). The hypothesis is
supported.
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Table 23
Jonkheere-Terpstra trend statistic
Pairwise comparison of the QOL- physical function
Visit

1

Pairwise
comparison
*CC < PC

Statistic
T JT = 740.5, z = 3.0, p = .004

*CC < PS
PS = PC

T JT = 959, z = 3.2, p = .002
TJT = 1,043.5, z = -.329, p = .629

2

No differences
*CC < PC
*CC < PS
3
PS = PC
*indicates a difference
CC = Care coordination
PC = Primary care
PS = psychiatry

TJT = 1,419.5, z = 1.4, p = .150
TJT = 595, z = 2.7, p = .01
TJT = 356.5, z = 2.36, p = .027
TJT = 629, z = 89.23, p = .567

c. Hypothesis 3: When comparing by provider types Role Physical scores in
the SF-36 scale will be highest in psychiatry, and primary care and lowest
in care coordination.
There were differences found between provider types at visit three T JT = 1,617, z =
2.3, p = .023, but not at visit one T JT = 2,647, z = 1.9, p = .055, or visit two, TJT =
1,368.5, z = 1.05, p = .294. Care coordination had poor role-physical scores compared
to psychiatry at visit two. (Table 22) for statistical pairwise comparisons. The
hypothesis was partially supported.
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Table 24
Jonkheere-Terpstra trend statistic, pairwise comparison of the QOL- role
physical
Visit
1

Pairwise
comparison
CC compared to PC

Statistic
T JT = 293.5, z = .938, p = .522

*CC < PS

T JT = 563, z = 2.4, p = .038

PS compared to PC
No pairwise
2
comparison
No pairwise
3
comparison
*indicates a difference
CC = Care coordination
PC = Primary care
PS = psychiatry

TJT = 760.5, z = 1.31, p = .286
T JT = 2,647, z = 1.9, p = .055
TJT = 1,368.5, z = 1.05, p = .294

d. Hypothesis 4: When comparing by provider types Bodily pain scores in
the SF-36 scale will be highest in psychiatry, and primary care and lowest
in care coordination.
There were differences between provider types found at visit one T JT = 2,818.5,
z = 2.8, p < .01 and visit three, T JT = 1,627.5, z = 2.4, p = .019. Pairwise comparisons
were completed for these visits (Table 23). Care coordination patients had more severe
pain than primary care and psychiatry. The hypothesis is supported.
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Table 25
Jonkheere-Terpstra trend Statistic-Pairwise comparison of the QOLBodily Pain
Visit
1

2
3

Pairwise
comparison
*CC < PC

Statistic
T JT = 694, z = 2.4, p = .024

*CC < PS

T JT = 944.5, z = 3.0 p = .004

PS compared to PC
No pairwise
comparison

TJT = 1,180, z = .717, p = .710

*CC < PS

TJT = 599, z = 2.78, p = .008

CC compared to PC
PC compared to PS
*indicates a difference
CC = Care coordination
PC = Primary care
PS = psychiatry

T JT = 2,647, z = 1.9, p = .055

T JT = 333.5, z = 1.84, p = .098
T JT = 695, z = .284, p = .851

e. Hypothesis 5: When comparing by provider types, General Health scores
in the SF-36 scale will be highest in psychiatry and Primary care and
lowest in care coordination.
There were no differences between provider type noted for any visit. Visit one
results are T JT = 2,469, z = 1.03, p = .303. Visit two results are T JT = 1,329.5, z =
.748, p = .455. Visit three results are T JT = 1,455.5, z = 1.075, p = .282. This
hypothesis is not supported.
4. Do patients with MDD or DDNOS who are participating in a pharmacogenetics
testing study have differences in the mental components (vitality, social function,
role emotion, and mental health) of the SF-36 scale by provider type?
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Table 26
Estimated Marginal Means for Mental Composite Score
95% Confidence
Interval
Lower
Upper
Provider type
M
SE
df
Bound
Bound
Care Coordination
41.30 2.01 120.30
37.31 45.29
Primary Care
Psychiatric Care

28.73

1.59 121.31

25.59

31.87

33.33

1.35 111.14

30.65

36.01

Care coordination had better quality of life for their mental health than primary
care or psychiatry patient’s F (2,118) = 12.01, p <. 001. MCS was different at visit one T
JT

= 1,542.5, z = -3.56, p < .001.
a. Hypothesis 1: When comparing by provider types, mental composite
scores of the SF-36 scale will be highest in primary care and care
coordination and lowest in psychiatry (Table 24).
Care coordination had better mental health quality of life scores than primary care

T JT = 152, z = -4.765, p <. .001, and psychiatry T JT = 224, z = -4.7, p < .001. There were
no differences between primary care and psychiatry, T JT = 1,166.5, z = .610, p = .729.
This hypothesis was not supported.
b. Hypothesis 2: When comparing by provider types, Vitality scores in the
SF-36 scale will be the highest in primary care and care coordination and
lowest in psychiatry.
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There were no differences among provider types or visits for vitality scores.
Therefore, there were no pairwise comparisons. At all visits vitality did not differ, visit
one, T JT = 1,999.5, z = -1.3, p = .19, visit two, T JT = 1,071, z = -1.23, p = .22 and at visit
three T JT = 1,109, z = -1.49, p = .136. This hypothesis was not supported.
c. Hypothesis 3: When comparing by provider types, Social function scores
in the SF-36 scale will be the highest in primary care and psychiatry and
lowest in care coordination.
There were no differences among provider types or visits. Therefore, there were
no pairwise comparisons. At all visits social function did not differ, visit one, T JT =
2,130, z = -.67, p = .51, visit two, T JT = 1,406.5, z = 1.35, p = .18 and at visit three T JT =
1,432, z = .913, p = .361. This hypothesis was not supported.
d. Hypothesis 4: When comparing by provider types, Role Emotional scores
in the SF-36 will be the highest in primary care and care coordination and
lowest in psychiatry.
There were no differences among provider types or visits. Therefore, there were
no pairwise comparisons. At all visits role emotional scores did not differ, visit one, T JT
=

2,010, z = -1.3, p = .21, visit two, T JT = 1,397, z = 1.3, p = .21 and at visit three T JT =

1,397, z = 1.3, p = .205. This hypothesis was not supported.
e. Hypothesis 5: When comparing by provider types, Mental Health scores
will be the highest in primary care and care coordination and lowest in
psychiatry.
There was a difference between providers at visit one, T JT = 1,572.5, z = -3.43, p =
.001. Care coordination had better mental quality of life than primary care T JT = 236, z
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= -3.67, p < .001, and psychiatry T JT = 283, z = -4.1, p < .001. However, there was no
difference found between primary care and psychiatry T JT = 1,053.5, z = -.25, p = .4.
This hypothesis was not supported.
5. How does the study population’s genetic phenotype (poor metabolizer,
intermediate metabolizers, ultra-rapid metabolizer) in all provider types compare
to the general population genetic phenotypical frequency rates?
Table 27
Comparison of Genetic phenotypes to Caucasian
CYP
CYP
CYP
CYP
CYP
CYP
2D6
2B6
2C9
2C19
1A2
3A4
%
%
%
%
%
%
n=1
n=2
n=2
n=2
n = 13 n = 1
PM
study %
10.7
0.8
0.8
1.7
1.7
1.7
Caucasian %
10
2 to 4
2 to 20
n = 49 n = 41 n = 66 n = 47
n = 109 n = 103
EM
study %
40.5
33.9
54.5
38.8
90.1
85.1
Caucasian %
48
60
14 to 44
n = 30 n = 25 n = 16 n = 28
n=2
n=1
IM
study %
24.8
20.7
13.2
23.1
1.7
0.8
Caucasian %
35
35
24 to 36
n = 25 n = 43 n = 32 n = 2
n=3
n = 10
IM^
study %
20.7
35.5
26.4
1.7
2.7
8.3
n=0
n=0
n=1
n = 37
n=0
n=0
UR
study %
0
0
0.8
30.6
0
0
Caucasian %
0
0
0
30
0
0
PM (poor metabolizer), EM (extensive metabolizer), IM (intermediate metabolism), IM^
(Intermediate metabolism clinical indication), UR (ultra-rapid metabolism).
For allelic distributions refer to Appendix H (Tables 26 – 31). Genetic results of
the sample, mimic the Caucasian population (Table 26).
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Additional Analysis
As a secondary analysis, not included in the research questions, an evaluation of
the “acknowledgment form” was conducted. This form was described in previous
chapters and is listed in Appendix A. This form was given to all providers with the
PGXr. Providers were instructed to return the form indicating a ‘yes’ or ‘no’ response to
any medications changed because of the PGXr. In addition, they were asked if the patient
acknowledged that the medication changes were based on the PGXr, and another ‘yes’
and ‘no’ response. This yes or no acknowledgement was added to the mixed linear
model as a covariant for the study. Participants who had providers return the form were
included in the analysis.
All participants with missing documents were excluded from this analysis, so the
total sample for each group included 22 care coordination patients, 29 primary care
patients, and 49 psychiatry patients. A summary of the breakdown of yes and no
responses by provider group is below (Table 28).
Table 28
Providers indicating no or yes to acknowledgement form
No percent
Care coordination

Yes percent

2

7.7

20

76.9

Primary care

10

24.4

19

46.3

Psychiatry

26

48.1

23

42.6
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A comparison of patients who received responses for the acknowledgement form and
those who did not had results as listed in the following tables (Table 29-32).
Table 29
Depression severity (PHQ9) interaction with acknowledgment by group

Parameter
Care coordination with
yes response
Care coordination with
no response]

df

t

99.615

-4.399

.000*

-9.293293

-3.515749

97.820

-1.158

.250

-11.013160

2.898428

Primary care with no
response

91.824

-.353

.725

-4.051406

2.827432

Primary care with yes
response

93.473

.503

.616

-2.111065

3.544942

Psychiatry group with
yes response

87.831

15.830

.000*

13.108840

16.872816

Psychiatry group with
'NO' response

88.643

-1.438

.154

-4.461598

.714919

*significant finding

Sig.

95% Confidence Interval
Lower
Upper
Bound
Bound
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Table 30
QIDS and acknowledgment

Std.
Estimate Error
Care coordination
"No'
-.54 2.65
acknowledgement
Care coordination
'yes'
-1.97
.99
acknowledgement
Primary Care 'No'
.11 1.29
acknowledgement
Primary care
.99
'Yes'
.74
acknowledgment
Psychiatry 'NO'
-.34
.90
acknowledgement
Psychiatry 'Yes'
12.02
.65
acknowledgement
*indicates significant result

df

t

192.82

231.58

Sig.

-.20

95%
Confidence
Interval
Lower Upper
Bound Bound

.84

-5.78

4.69

-1.97 .049*

-3.94

-.007

227.69

.09

.93

-2.43

2.66

237.43

.75

.46

-1.21

2.69

243.94

-.38

.70

-2.12

1.43

245.62

18.3 .000*

10.72

13.30

Table 31
Mental Composite Scores and acknowledgement
95% Confidence Interval
Lower
Upper
Bound
Bound

Parameter

df

t

Sig.

Care coordination ‘Yes”
response

97.63

2.025

.046*

.29

28.64

96.96

2.71

.008*

2.16

14.03

94.68

-.68

.49

-9.70

4.7

96.24

-1.50

.13

-10.57

1.45

95.06

-.17

.86

-5.94

4.97

96.84

19.41

.000*

40.15

49.29

Care coordination “no’
response
Primary care ‘no’ response
Primary care ‘yes’ response]
Psychiatry ‘no’ response
Psychiatry ‘yes’ response
*indicates significant findings
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Table 32
Physical composite score interaction with acknowledgment

Parameter
Care coordination ‘no’
response
Care coordination ‘yes’
response
Primary care ‘no’
response
Primary care ‘yes’
response
Psychiatry ‘no’ response
Psychiatry ‘yes’ response

df

t

95% Confidence
Interval
Lower
Upper
Sig.
Bound
Bound
.369
8.768762
23.417909
.007*
-2.599955
16.191572

94.614

-.904

96.993

-2.744

97.516

1.042

.300

-3.947478

12.678172

98.018

1.132

.260

-2.970266

10.858393

96.534

.465

.643

-4.801860

7.738867

96.844

19.421

.000* 40.146671

49.286616

When the statistical model was conducted, some interesting interactions were
found regarding the change in depression severity scores. Both the care coordination
group (b = -6.40, t = -4.399, p <.0001) and the psychiatry groups (b = 14.99, t = 15.83, p
<.0001) who had ‘yes’ responses to the acknowledgment of medication change had
interaction for changes in depression severity of provider type, and acknowledgment.
Primary care patients had no interaction. Also, these two groups had interactions of
physical and mental composite scores (Table 30 and 31). This model takes into
consideration change over visits for depression severity, study provider, and
acknowledgment status.
This chapter has presented the results of this study, and a discussion of the major
findings will follow in chapter 5. This study was conducted to evaluate by provider type
including care coordination, primary care and psychiatry, the change of depression
(PHQ-9), depressive symptoms (QIDS-SR16) and quality of life (SF36) over time in a
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population of patients diagnosed with MDD or DDNOS while participating in a study for
pharmacogenetics testing. This chapter presented the quantitative results using mixed
linear models, Jonkheere-Terpstra trend statistics, one-way ANOVA, frequencies, and
used descriptive statistics to answer the research questions presented in chapter 3.
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CHAPTER 5
Discussion
This Chapter discusses the results of the findings. Strengths and limitations of the
combined data set are discussed. Additionally, clinical implications will be considered
with recommendations for future research. The study was conducted to evaluate by
provider type including care coordination, primary care and psychiatry, the change of
depression (PHQ-9), depressive symptoms (QIDS-SR16) and quality of life (SF36) over
time in a population of patients diagnosed with MDD or DDNOS while participating in a
study for pharmacogenetics testing
Participant Demographics
There was no difference between the three groups regarding age or gender
proportions. However, this study had slightly more females than males and more females
than other studies of depression. An evaluation of insurance type showed that most of
primary care and psychiatry had private insurance, while care coordination participants
mostly had Medicaid, which was indicative of the population.
Most of the participants were married or single, but care coordination, had a
higher percentage of divorced patients and most resembled other studies of depression.
Primary care had the lowest percentage of participants who were employed, and
psychiatry patients had the highest percentage who were employed. Care coordination
had the highest percentage of disabled participants, and psychiatry had the highest
percentage of retired participants. Care coordination is a program that is offered to
patients who are Medicaid or Medicare, who meet specific criteria for physical and
mental illness, so this difference is not unexpected.
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Care coordination had twice as many chronic health conditions and twice the
number of medications than both primary care and psychiatry groups. It is possible that
care coordination participants had a decreased emphasis on mental health because of
physical health complications. More medication use can also complicate prescribing for
depression and affect medication pharmacokinetics and thus effectiveness.
Primary care and psychiatry studies controlled for mental health conditions. Care
coordination did not control for other mental health conditions, allowing for mental
health comorbidities. Interestingly, there was no difference between groups concerning
number of mental health conditions.
Discussion of Research Questions
Overall group changes. All patients together, regardless of group, showed a
decrease in depression severity, depression symptoms and an increase of mental
composite quality of life from visit one to visit three. Participants baseline scores started
at high moderate and decreased to the low moderate level at visit three for depression
severity. The decrease in symptoms indicated a change from moderate symptoms at
baseline to minimal at the third visit. This decrease in depression severity and symptoms
also resulted in an improvement in mental quality of life. But, quality of life reveals no
change in physical composite scores. Overall, patients who were receiving treatment
through the study improved for all measures, excluding physical composite scores.
Primary care and psychiatry groups had higher numbers of participants which may have
influenced these total sample results. Care coordination had the fewest number of
participants and therefore the smallest impact on overall changes for the group as a
whole.
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Depression severity (PHQ9).
The objective for this study was to evaluate differences in depression severity
between groups. Results indicate that care coordination was less depressed and had lower
depression severity, than primary care and psychiatry patients. Level of depression was
similar between primary care and psychiatry patients. Additional analysis assessed
change over time in each provider group. Because participants in care coordination are
complex patients, there was a question about the inability of patients to decrease
depression severity during the three time points, and this proved true. Care coordination
did not improve their depression severity over time. However, care coordination
participants had low moderate levels of depression to begin the study, and improvements
from that level of depression may take more time and higher sample size to see statistical
improvements. On the other hand, this may be representative of fluctuations within a
chronic underlying depression that is comorbid with chronic illness.
Primary care and care coordination participants had decreases in their depression
severity from baseline to time three. About fifty percent of participants in both groups
were able to reduce their depression from baseline levels of moderate to severe
depression to mild depression category. This is a clinically important point for this study,
suggesting that primary care providers are as effective as psychiatrists in managing
depression severity.
The conclusions for depression severity in this study are consistent with previous
studies, such that primary care and psychiatry patients tended to have similar depression
severities. Primary care and psychiatry levels were in the severe depression range. There
were decreases in both primary care and psychiatry in depression severity scores over the
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course of three visits, but no change in care coordination. Mostly likely, this lack of
change is a reflection of the lower baseline scores in the care coordination group, and that
there were no inclusion criteria to control for higher depression rates.
Depression symptoms (QIDS).
There was no interaction between provider type, change over time and depression
symptoms. However, it is interesting that compared to an analysis of combined
participants which indicated improvements in symptoms, the individual provider groups
did not all show decreases. Care coordination participants did not have decreases in
symptoms, which was probably attributed to health problems which potentially interfered
with the patient’s ability to separate depression related symptoms from illness related
symptoms.
Both primary care and psychiatry participants had decreases in their depression
symptoms. This finding suggests that those who see primary care providers, but are not
part of the care coordination program are able to discern differences in depression
symptoms compared to chronic illnesses. While not measured, another possible factor is
that they had higher health literacy. Participants mean symptoms at baseline were higher
in primary care than psychiatry patients, but not significantly so. This finding may lend
validation to previous studies which indicate more somatic complaints noted in primary
care than psychiatric patients. Mean symptoms were also consistent with previous
studies conducted.
Quality of Life (SF36)
Physical Composite Score. The SF-36 instrument assesses physical quality of
life and mental quality of life as two main scores. Low scores on the quality of life scale
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indicate poor quality of life while high scores indicate better quality of life. The care
coordination group had poor physical quality of life, in ‘physical composite scores’,
‘physical function’ scores, ‘role physical’ scores, and ‘bodily pain’ scores, compared to
the primary care and psychiatry groups. Having low scores at most of the visits for care
coordination patients indicates poor daily physical function. Patients in care coordination
tend to have more chronic conditions, some of which are pain related. Previous literature
as discussed in chapter three, indicates that depression contributes to increasing disability
with activities of daily living when a physical impairment also exists. Previous studies
have reported that primary care patients had more impaired quality of life over psychiatry
patients. Our sample shows that primary care and psychiatry patients are similar in
physical function with little problems in completing tasks of daily physical life.
Interestingly, there were no differences in patient’s self-evaluation of ‘general
health’ among provider types. General health measures on the quality of life indicate
one’s outlook on their future health. This indicates that all patients had a similar outlook
on their future health.
Care coordination patients had higher ‘mental composite score’s than primary
care and psychiatry patients. This was an unexpected finding as the components of the
‘mental composite score’ include the four subscales of ‘vitality’, ‘social function’, ‘role
emotion’ and ‘mental health’. The only subscale differences noted for mental composite
scores between provider types were the overall ‘mental composite score’ and ‘mental
health score.' Primary care and psychiatry groups had lower ‘mental composite scores’
indicating higher levels of stress and depression-related social disabilities than the care
coordination group. Also, primary care and psychiatry patients had poor ‘mental health
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scores’, which indicates a more persistent and sustained depression. In these two areas,
care coordination patients had a better quality of mental health than either primary care or
psychiatry patients. Again, this may be related to primary care and psychiatry groups
having higher PHQ9 scores at study entry, which signifies higher levels of depression.
Primary care patients and psychiatry patients tended to have poor quality of life, and high
levels of depression. This combination of depression and quality of life is similar to
previous studies.
This study found that the care coordination group differed from both primary care
and psychiatry groups for depression severity PHQ9, and SF36. Interestingly, care
coordination patients had less severe depression and high quality of life scores, indicating
a good quality of life. Studies of depression that also evaluated the quality of life
reported that those with more severe levels of depression had a poor self-reported quality
of life measurement. The fact that quality of life scores were higher in care coordination
patients, could be explained by the differing inclusion criteria. The care coordination
group did not have a baseline depression score restriction of ≥ 10 while primary care and
care coordination did have this limitation.
Pharmacogenetic phenotypes. Pharmacogenetics testing was completed on
most of the participants, with a pharmacogenetic guidance report (PGXr) conducted by
genetic pharmacists for the study sample. The genetic data was collected for the three
individual studies but were combined for this study. This study reported the frequency of
phenotypes as they relate to the general population.
All three studies had a pharmacogenetics component, and this question was
simply to describe our study sample. Reported genetic phenotypes were very similar to a
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general Caucasian population, which means that this study may be generalized to a larger
population of Caucasians. There was initially speculation that because patients in care
coordination had such complex medical conditions paired with large numbers of
medications, that perhaps this study sample may have a higher incidence of genetics
related to poor enzyme function in the liver to metabolize medications appropriately.
However, results were similar to reported population averages.
Acknowledgement forms
Response to the acknowledgment forms was highest for care coordination and
lowest for primary care. Both the care coordination and psychiatry groups had
improvements in depression severity and symptoms in those patients who the provider
returned the acknowledgment form with a “yes” as opposed to a “no” response.
Interestingly, care coordination did not have a significant decrease of depression related
symptoms overall. This may be for several reason including the possibility that provider
engagement, or medication changes based on pharmacogenetics was a mediator to
change.
When PCS and MCS for the quality of life measures were evaluated, care
coordination patients showed an interaction of provider type and PGXr acknowledgement
either way, ‘yes’ or ‘no’, for MCS. Both yes and no acknowledgement were significant.
This finding may be because there was a small sample size and small change in MCS or
related to contact with care coordination. The psychiatry group had an interaction as
well, but only for those who answered ‘yes’ to the acknowledgement. Primary care
showed no interactions.
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In addition, care coordination and psychiatry groups also had significant changes
for PCS for those whose provider returned the form with a “yes”. Primary care again had
no change. It is easy to suspect that there were changes in physical quality of life in the
care coordination patients because this sample of patients scored very low in this
category, and any improvement could be noteworthy. In addition, if medications were
made based on the PGXr with the patient’s acknowledgment the patient could have a
sense of improvement. It is unclear, however, this author speculates that patients were
more engaged by the research team and residents regarding changes that occurred in
psychiatry.
The PGXr acknowledgement form and process results need more clarification and
study. It is unclear if the form is a good indication of patient understanding and
acknowledgment to medication changes based on pharmacogenetics because it was a
provider form. Patients did not fill out the form and return. A more controlled study,
with a questionnaire related to patient acknowledgement of and understanding of changes
made because of pharmacogenetics would have better validity. However, the finding
suggest that care coordination was more aware of the processes, and changes based on
this study’s findings. This conclusion, however, must be viewed with caution based on
these results. Evaluation of patient’s awareness of the pharmacogenetics
processcertainly needs future more controlled study.
Nursing Theory relationship
Dorothea Orem’s SCDT explains factors that specifically relate to the care
coordination participants. For example, three perspectives contribute to self-care,
conditioning factors, psychophysiological factors of health and disease and behavioral
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resources and demands. The care coordination participants had a combination of
physical and mental health needs, and many were lacking resources. Some care
coordination participants were homeless, lacked financial resources and had limited
health literacy. Nursing guidance is important when patients have low health literacy to
help guide patients in, for example, behavioral changes and understanding medications.
The lack of health literacy, lack of financial resources and physical complication to basic
everyday activities, can cause deficits in self-care abilities and these are evident in the
low physical composite scores noted in the care coordination group compared to the
primary care and psychiatry group. These deficits may be filled by nursing resources and
programs such as care coordination and care transitions programs.
The deficits noted in the quality of life for the physical component in care
coordination reflect lack of self-care agency. Self-care agency is the power and ability to
care for oneself. Patients in the care coordination group had worse physical scores in
‘role-physical’ and ‘physical function’ on the quality of life measure. ‘Role physical’
indicates deficiencies at work or with employment due to the interference of physical
problems. In addition, ‘physical function’ is a limitation of daily activities of living. The
care coordination group had the highest percentage of physically disabled and
unemployed participants, which is evidenced in the physical quality of life total score and
sub-scale scores. These indicators of quality of life reflect a need for nursing
intervention.
Strengths of the study.
This study had several strengths such as similarities in study design between the
three samples, use of the same questionnaires and similarities of visit timelines. Having
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care coordination as a group comparison added more information to previously published
literature and filled the literature gap. The willingness of providers and nursing staff to
assist with this study also was a strength for data collection and the reduction of patients
becoming lost-to-follow-up.
This study added a unique picture of depression in three unique samples.
Evaluation of primary care and psychiatry patient’s depression has been previously
researched. The addition of care coordination with this the population’s physical
limitations, low health literacy, high health care utilization and health complexities added
an interesting perspective to the comparison.
Challenges and Limitations
There were multiple challenges and limitations beginning with enrollment. When
the three studies were designed, it was predicted that the care coordination study would
complete enrollment quickly. However, protocol inclusion criteria which restricted
insurance type limited the sample size; therefore, an amendment was completed. While
recruitment increased, the process was slow and numbers remained low for care
coordination. The primary care group had no research coordinator at the clinics to guide
the research process, so enrollment and follow-up visits were completed over the phone
and through the mail. This process increased the number of missed or delayed visits. The
psychiatry group had the highest enrollment number as the study was overseen by
medical residents and research staff Psychiatry also had the fewest missed visits and
patients lost to follow-up. At the time the analysis was completed, participants were at
various stages of the study and contributed to missed visits and incomplete data
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collection. Missing data can be a significant problem associated with increasing bias, and
creating issues with sample size.
Self-report measures are also a limitation in survey research because the
researcher must rely on a patient’s ability to be introspective and truthful about one’s
condition. Some problems may occur because participants were unwilling to answer
certain questions or avoided truthful responses. Additionally, the patient answered the
same questionnaires multiple times, which may have caused the patient to anticipate
questions and report on them differently. Furthermore, the choice of participating clinics
for all provider types, care coordination, primary care, and psychiatry was limited to a
convenience sample of within-health system participation. The lack of randomization can
lead to biased results..
Additionally, the purpose of the care coordination study was not originally to
make a comparison between groups, and so the depression severity inclusion criteria
were slightly different than the primary care and psychiatry studies. This had a potential
influence on the outcomes noted for care coordination. Along with this difference, the
care coordination participants had restrictions on the type of insurance that the patient
could have to enter the study.
Future Implications. Future study recommendations include the addition of the
patient activation measure (PAM), to fully understand how engaged the care coordination
patient is compared to primary care or psychiatry. Using a measure of patient activation
may offer data and insight on components associated with self-care activities.
This study evaluated overall numbers of symptoms using the QIDS self-report
form. However, an evaluation of the types of symptoms experienced overall and between
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each group may shed more light on the care coordination group’s differences.
Additionally, an understanding of depression symptoms and which specific symptoms
were reduced may be important to understand the overall effect and impact on patients.
Other studies found that most people experienced sexual side effects when on
antidepressant medication. This analysis was not completed with this study but will be
conducted later.
Cost outcomes are an important measure of clinical use. Does pharmacogenetics
testing improve future cost expenses to patients and health systems? This has yet to be
addressed. The centers for Medicare and Medicaid, are reimbursing some
pharmacogenetics testing such as for clopidogrel, an antiplatelet medication, which has
been shown to have clinical utility and decreases costly health and economic outcomes
for both patients and hospital systems. However, reimbursements are few and far
between for other indications such as in mental health applications.
Nursing influence on outcome was not the primary goal of this study; however,
this study contributes to baseline understanding of depression in the care coordination
sample compared to primary care and specialty care settings. Future studies are needed
to understand nursing’s influence for improving outcomes for patients with depression
through participating in care management or care coordination. This study shows that the
care coordination participants are a unique study sample with individualized needs which
can be met with patient centered-care coordination. This study speaks directly the care
coordination competencies and nursing’s ability to provide care for those in self-care
deficit.
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Summary
This study evaluated differences in depression severity (PHQ9), depression
symptoms (QIDS), and quality of life (SF36) in three populations of patients being
treated by different providers. The three providers included care coordination, primary
care and psychiatry. The study compared patients from three provider groups who all
had major depression disorder, or depression diagnosis-not otherwise specified. All three
studies used the same questionnaires at the same intervals, PHQ9, QIDS, and the SF36.
Care coordination was different from primary care and psychiatry on many levels.
There were no inclusion criteria to control for baseline depression severity levels and
mental composite quality of health which revealed that care coordination participants
have lower depression severity compared to the other groups. This finding suggesting
that care coordination’s depression is not as severe as primary care or psychiatry patients
should be taken with caution since primary care and psychiatry inclusion criteria dictated
higher levels of depression for all participants. Care coordination group’s mental quality
of health is also much better than the other groups. Care coordination group had more
chronic illness and may be related to secondary depression caused by chronic illness. It
was clear that care coordination participants had more chronic conditions and more
complex situations because they also had the highest number of chronic diagnoses and
highest number of medications compared to primary care and psychiatry patients.
Overall, the chronic conditions found in care coordination appear to contribute to the
mild to moderate depression found in this population.
Care coordination was had less depression severity and less symptoms but better
mental quality of life than primary care and psychiatry patients. In addition, care
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coordination had more chronic conditions and polypharmacy use, which was reflected in
their poor quality of physical health scores. However, there were parallels found between
primary care and psychiatry patients. Primary care and psychiatry patients had similar
depression severity, similar depression symptoms and similar quality of life scores for
both physical and mental composite scores. Depression in the primary care population
has been studied as previously discussed in the literature review, and it has been
identified as having more somatic symptoms than patients in psychiatry. This finding
was not supported in this study, however, given a larger sample size, perhaps this would
have been the case. Overall, the similarities between primary care and psychiatry
patients was consistent with previous studies.
Conclusion
This study illustrates differences in care models which have the potential to
influence patient depression outcomes and that primary care and psychiatry patients
follow similar trends and characteristics. Pharmacogenetic care may influence patient’s
engagement, decrease depression severity and symptoms and improve quality of life.
Care coordination patients differ from primary care and psychiatry patients in depression
severity, depression symptoms and physical quality of life. At its most elemental, this
study has shown that care coordination participants have unique challenges and some
advantages over primary care and psychiatry patients. Care coordination participants
have multiple challenges, because they have complex chronic illness in combination with
mental health issues preventing or hindering activities of daily living. The strengths of
care coordination are the nursing leaders along with social workers who guide
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participants care, strengthen the process of transitions, and navigation of the complex
system of healthcare we have today
Additional strengths for the care coordination group are that they had less
depression and higher quality of life. Previous studies directed attention toward managed
care which might increase follow-through for patients and potentially better outcomes.
Nursing is situated to make a large impact on the possible outcomes for depressed
persons through care coordination. Additional nursing interventions in all three settings
would impact depression care and patient outcomes.
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Appendix A
Acknowledgment form
PGX-TIME STUDY
Psychotropic Genotyping panel research study
Physician RESPONSE TO GENOTYPING PANEL report
Patient Name____________________________________ DOB:___________________
Physician Response Plan as a result of the Psychotropic Genotyping Panel for research study.
_________No medication changes planned
_________Change in medication:
Current Medication:____________________________________
New Medication:_______________________________________
________Change in Medication DOSAGE:
Current Medication/DOSE_______________________________
New dosage:__________________________________________
Patient acknowledges medication change plans based on pharmacogenetic testing:
__________Yes
__________No
Date:________________
Physician Referring Patient to Study:_______________________________
Staff completing form:___________________________________________
Phone:________________________ Email______________________________
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Appendix B
Pharmacogenetic resources

Resources for Clinical Guidelines in Pharmacogenetics

Information available

www.pharmgkb.org

CPIC guidelines, DPGW

http://medicine.iupui.edu/clinpharm/ddis/main-table/

CYP 450 pathways
pharmacogenomics
education

https://pharmacogenomics.ucsd.edu/
http://www.nhlbi.nih.gov/research/resources/geneticsgenomics/pgrn

Pharmacogenomics at NIH
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Appendix C
Pharmacogenetic CYP substrate pathways of Antipyschotics

1A2
amitriptyline
(Elavil®)
fluvoxamine
(Luvox®)
asenapine
(Saphris®)
olanzapine
(Zyprexa®)
clozapine
(Clozaril®)
pimozide
(Orap®)
Thiothixene
(Navane®)
trifluoperazin
e
(Stelazine®)

2B6
paroxetin
e
(Paxil®)

2C9

2C19

2D6

3A4,5,7

amitriptylin
e (Elavil®)
fluoxetine
(Prozac®)

amitriptyline
(Elavil®)
escitalopram
(Lexapro®)

fluvoxamine
(Luvox®)
amitriptyline
(Elavil®)
clomipramin
e
(Anafranil®)
Desipramine
(Norpramin)
doxepin
(Silenor®)
trimipramine
(Surmontil)
amoxapine
(Ascendin®)

alprazolam
(Xanax®)
diazepam
(Valium®)

Citalopram
(Celexa®)

CYP 2D6
(cont)
haloperidol
(Haldol®)
perphenazine
(Prolixin®)

risperidone
imipramine
(Risperdal®)
(Tofranil®)
thioridazine
fluoxetine
(Mellaril®)
(Prozac®)
zuclopenthixol nortriptyline
(Clopixol®)
(Pamelor®)
iloperidone
protriptyline
(Fanapt®)
(Vivactil®)
aripiprazole
paroxetine
(Abilify®)
(Paxil®)
quetiapine
(Seroquel®)
chlorpromazin
e
(Thorazine®)
Bohlen, Mattheissenn, Weisser, 2014. Avera Institute for Human Genetics
psychotropic panel, unpublished

midazolam
(Versed®)
triazolam
(Halcion®)
(SSRI)
vortioxetine
(Brintellix)
vilazodone
(Biibryd®)
escitalopra
m
(Lexapro®)
Citalopram
(Celexa®)
lurasidone
(Latuda®)
aripiprazole
(Abilify®)
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APPENDIX D
Institutional Review Board Documents
March 30, 2015
Julie Kittelsrud, CNP Avera
Research Institute 2020 S. Norton
Avenue Sioux Falls SD 57015
Dear Ms. Kittelsrud:
Regarding Our Study # 2014.079
Protocol Title: Evaluation ofPharmacogenetic (PGX Testing in a Mental health
population and Economic Outcomes (PGX-Time)
This is to inform you that the Avera IRB has reviewed your request regarding the
above referenced research study. This is to confirm that I have approved your
request.

•
•
•
•

Our Internal Number: 7770
The following items were reviewed
Protocol Amendment 2, dated 24-Mar-2015
Patient Schedule of Participation, Amendment 2, dated 25-Mar-2015
MMAS-8 Coding Questionnaire
PAM-MH Questionnaire
The study is subject to continuing review on or before 1/21/2016. You are reminded
that you are required to report any serious reactions to the Avera Institutional
Review Board within ten (10) business days of it occurrence (or your knowledge
thereof).
Please note that changes to the study as approved must be promptly reported
and approved. Some changes may be approved by expedited review; others
require full Committee review. Contact the Avera Institutional Review Board, at
(605) 322-4755, if you have any questions or require further information
regarding this IRB Action.

Respectfully yours,
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APPENDIX D
Matthew Stanley, D.O.
AMG University Psychiatry associates 4400 W. 69th Street
Sioux Falls SD 57108
RE: Our Study #2014.081
Dear Dr. Stanley:
Meeting Date: 12/17/2015
Protocol Title: Pharmacogenetic testing in an outpatient population of patients with
Major Depressive Disorder or Depressive Disorder not otherwise specified with Avera
University Psychiatry Associates.

This is to inform you the Avera IRB renewed its approval of the above research study. The
renewal is granted for an additional 12 months.
The Effective date of the renewal is 12/17/2015: The approval period will expire on
12/16/2016
The following items were reviewed:
• Continuing Review Report dated 3-Dec-2015
• Informed Consent dated 23-Jan-2015
All conditions for continued approval during the prior approval period remain in
effect. These include, but are not necessarily limited to the following requirements:
• A stamped copy of the most current Informed Consent Document (as noted
above) is included. No other consent documents should be used. Each subject must
sign the approved ICD prior to initiation of any protocol procedures. The original
signed informed consent document must be placed in each subject’s
medical/research chart. In addition, each subject must be given a copy of the
signed consent document.
•

All protocol amendments and changes to approved research must be submitted to the
IRB and not be implemented until approved by the IRB except where necessary to
eliminate apparent immediate hazards to the study subjects.

•

Significant changes to the study site and significant deviations from the research protocol
must be reported.

Please contact the Avera Dept of Human Subjects Protection (DHSP) at (605) 3224706 if you have any questions about the terms of this approval.
Sincerely yours,

Sandra G. Ellenbolt, CIM, JD
Director, Department of Human Subjects Protection/IRB Chair
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AMG University Psychiatry associates
4400 W. 69th Street Sioux Falls SD
57108

APPENDIX D

Dear Dr. Stanley:
Regarding Our Study # 2014.081
Protocol Title: Pharmacogenetic testing in an outpatient population of patients
with Major Depressive Disorder or Depressive Disorder not otherwise
specified with Avera University Psychiatry Associates
This is to inform you that on behalf of the Avera IRB I have reviewed your request regarding
the above referenced research study. This request qualified for expedited review under FDA
and NIH (OHRP) regulations. This is to confirm that on behalf of the Avera IRB I have
approved your request.

•
•
•
•
•
•
•
•

Our Internal Number: 7678
The following items were reviewed and approved:
UPA Protocol Amendment 1 1.23.15
UPA PGx Patient invitation letter Amend 1, 1.23.15
UPA PGx Schedule of Participation Amend, 1.23.15
UPA Patient Packet letter Amend 1, 1.23.15
UPA Questionnaire packet letter Amend 1, 1.23.15
FIBSER questionnaire
Beck Depression Inventory II
Telephone consent Script
The requested changes to the protocol have been approved.
The study is subject to continuing review on or before 1/21/2016. You are reminded that you
are required to report any serious adverse events to the Avera Institutional Review Board within
ten (10) business days of its occurrence (or your knowledge thereof).
Please note that changes to the study as approved must be promptly reported and approved.
Some changes may be approved by expedited review; others require full Board review. Contact
the Avera Institutional Review Board, at (605) 322-4755, if you have any questions or require
further information regarding this IRB action.
Respectfully yours,
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APPENDIX E
Supporting documents for Informed Consent
AVERA HEALTH PLAN- PGX TIME
PSYCHOTROPIC GENOTYPING PANEL RESEARCH STUDY
SCHEDULE OF PARTICIPATION
visit 1A
Screening
(letter/p
Visit 1
Visit 2
Visit 3
Stabilization
hone
contact)
3 months or
Month Month
Day 0
Month 1
longer
2
3
Procedure
Enter Care Coordination
Informed consent for the
PGX study
Current medications
Medical history
Demographics
Adverse Events
Questionnaires
Pharmacogenetic testing
PGx testing (blood
drawn and sent to
AIHG)
PGX recommended
changes begin

Visit 4

Visit 5

Month
6

Month
12

x
x*1

x*1

x*1

x*1

x*1

x*1

x*1

x
x
x

x

x

x

x

x

x

x
x

x
x

x
x

x
x

x
x

x
x
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*1. Informed consent may be completed on or before day 0, and is an ongoing process throughout the study.
*4. Short-Form-12, Quality of Life measurement
*5 STARD-Patient rated Inventory of Side Effects.

APPENDIX E

The Patient Health Questionnaire-9 (PHQ-9) is 9 questions and will ask you about your depression. It is used to help your care providers
understand the severity of your depression.
The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) is a 16 item questionnaire which assesses for symptoms related to
common symptoms experienced in depression.
The Short Form-36 (SF-36) health outcomes measure is 36 questions in length and addresses physical, social and emotional aspects about your
health.
The STAR*D-Patient rated Inventory of Side Effects (STAR*D-PRISE) is 20 questions and will ask you about any side effects that may be related to
taking antidepressant medications.
Frequency, Intensity and Burden of Side Effects (FIBSER) scale asks 3 questions about the frequency, intensity and burden of your side effects.
The following two Questionnaires will be taken by 100 participants at two time points (Day 0) and Month 3:

•

Patient Activation Measure-Mental Health (PAM-MH) is a 13 item questionnaire which asks you about your confidence level and
knowledge about your health care.
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APPENDIX E
Supporting documents for Informed Consent
Avera Institute for Human Genetics
Protecting Your Rights and Privacy as a Research Participant

Your privacy is very important to us. Like any other clinic or hospital visit, we are required to keep
your personal and medical information confidential before, during, and after your visit.

Our dedication to privacy extends beyond our doctors and nurses to include everyone employed
in our healthcare family. We want you to feel safe knowing your personal and medical information
is protected throughout Avera McKennan’s entire healthcare system.

How will my personal information be protected?
Information collected for research studies is confidential. Data collected and the specimen bank
are the property of the Avera Institute for Human Genetics. In the event of any publication
regarding this study, your identity will not be disclosed.

Employees of the Avera Institute for Human Genetics and the Avera Institutional Review Board
(IRB) may see parts of your medical records related to your participation in a study. The Avera IRB
is a group of scientific and non-scientific individuals that helps protect the safety and welfare of
subjects in research studies.

We will make every effort to protect your privacy. Here are just a few of the steps we will take:
•
•

•

We will keep your data coded and secure to ensure that your sample(s) and information
remain anonymous and can be used for quality research.
We will remove your name and other identifiers from your sample(s) and information, and
replace them with a code number. We will keep the list that links the code number to your
name separate from your sample(s) and information. Only a few of the researchers will have
access to the list and they sign an agreement to keep your identity a secret.
Avera safety monitors or committees, as well as the Avera IRB, may have access to your
records, but only in their role of ensuring the study is being done safely and correctly.
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•
•

•

Researchers who study your sample(s) and information will not know who you are.
Disciplinary actions, including termination of employment, may result if an employee tries
to determine your identity.
We will not give information that identifies you to anyone, except if required by law.
Information that is shared outside of the Avera Institute for Human Genetics may no longer
be protected by the federal privacy law called “HIPAA”; however, it will be protected as
described in this form and may be covered by other privacy laws.
The results of a study could be presented at a scientific meeting or published in an article,
but would be presented as a general analysis of many study donations and would not
include any information that would let others know who you are or any other study
participants are.

Who can see or use my information?
Signing a study’s informed consent document gives the researchers your permission to obtain,
use, and share information about you for the study, and is required in order for you to take part
in the study. Information about you may be obtained from any hospital, doctor, and other health
care provider involved in your care.

Information about you may include information about your health and your medical care before,
during, and after the study, even if that information wasn’t collected as part of the research study.
For example:
•
•
•
•
•

Hospital/doctor’s office records, including test results (X-rays, blood tests, urine tests, etc.)
Mental health care records (except psychotherapy notes not kept with your medical records
Alcohol/substance abuse treatment records
All records relating to your condition, the treatment you have received, and your response
to the treatment
Billing information

There are many reasons why information about you may be used or seen by the researchers or
others during the study. Examples include the following:
•
•
•
•

The researchers may need the information to check your test results or look for side effects.
Avera Institute for Human Genetics and government officials may need the information to
make sure that the study is done properly.
Organizations that are funding the study may need the information to make sure that the
study is done properly.
The researchers may need to use the information to create a data bank of information
about your condition or its treatment.
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What happens to information about me after the study is over or if I cancel my permission?
As a rule, the researchers will not continue to use or disclose information about you, but will keep
it secure until is destroyed, Sometimes, it may be necessary for information about you to continue
to be used or disclosed, even after you have canceled your permission or the study is over.
Examples of reasons for this include the following:
•
•
•

To avoid losing study results that have already included your information.
To provide limited information for research, education, or other activities. (This information
would not include your name, social security number, or anything else that could let others
know who you are.)
To help the Avera Institute for Human Genetics and government officials make sure that
the study was conducted properly.

If you have questions about your rights in the study, you should contact:
Avera Institutional Review Board
3900 West Avera Drive
Sioux Falls, SD 57108
(605) 322-4755
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Informed Consent for Psychotropic Genotyping Panel Research Study

First name: ____________________________ Last name:
______________________
DOB: __________________

Male

Female

Test to be completed: ____Psychotropic Genotyping Panel_________
Purpose of the Study
You are invited to volunteer to be in a research study to evaluate the effectiveness of determining
the right medications based on your genetic profile. This genetics testing uses a blood sample to
get a snap shot of how your liver will metabolize medications; it will not show risk for getting a
disease. The primary objective of this study is to draw blood and find out which medications,
based on your individual genetics, might work best in treating you. This type of testing is currently
available as a service at Avera and other laboratories; however, we hope that this study will
support and/or add to the use of this genetic testing in clinical practice.

You have been identified by your physician as meeting criteria for this research study. This blood
test is not a treatment; the genetic analysis, along with other information, will be considered by
professionals to make clinical medication recommendations for your treatment. With your
consent, your medical history, demographics, and list of medications will be accessed and utilized
by research staff to make these recommendations to the providers involved in your care. This
study will use questionnaires to measure the effectiveness in providing this genetic testing.

Study Involvement
If you consent to take part in this study, your physical involvement is limited to about 12 months
and will include informed consent, collection of a blood sample, standard care clinic visits, and
questionnaires taken about every 3 months over that time. You will need to visit an Avera
Laboratory draw location to have your blood drawn. Lab staff will collect two purple-top EDTA
tubes, with at least 2 ml (about ½ a teaspoon) in each tube. It may also be necessary for research
staff to contact you regarding questionnaires or for other information needed for the conduct of
the study. Your consent will also allow staff to access your medical records for the 12 months
prior to your enrollment into this research study. Please refer to the Psychotropic Genotyping
Panel Research Study Schedule of Participation for a more detailed explanation of procedures
and questionnaires. Also, with your consent, your blood sample will be stored in the Avera
Institute for Human Genetics (AIHG) Specimen Bank indefinitely for use in studying future genetic
and genomic issues. Your sample will be coded in order to protect your identity in any future
studies.

Privacy and Confidentiality
Your privacy is very important to us. We are required to keep your personal and medical
information confidential before, during, and after your clinic visit. At all times, Avera has
appropriate administrative, technical, and physical safeguards in place to protect the privacy of
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your personal health information. Your genetic report will be entered into your Avera electronic
medical record and will only be accessed by clinicians directly involved in your care and by
designated research staff involved in this study. Your genetic report is confidential to the extent
required by law and may only be released to other medical professionals with your written
consent. We want you to feel safe knowing our personal and medical information is protected
throughout Avera’s entire healthcare system. Our dedication to privacy extends beyond our
doctors and nurses to include everyone employed in our healthcare family.

Benefits and Risks of Participation
This pharmacogenetic test only looks at how your body processes (or metabolizes) medications,
providing clinicians with a tool for prescribing the safest and most effective medications, helping
avoid adverse effects. Your doctor will receive a report that tells which medications may help best
treat you. If you have "normal" metabolism, your doctor will prescribe medications based on
current best practice standards, the same as if you do not have this test.
Although the chance is small, there is a risk that someone could get access to the data
confidentially stored about you. There is also the risk someone could trace the information in a
scientific database back to you. Even without your name or other identifiers, genetic information is
unique to you. The Genetic Information Nondiscrimination Act (GINA) generally protects you
against discrimination based on your genetic information when it comes to health insurance and
employment. Please refer to the AIHG Protecting Your Rights and Privacy as a Research
Participant document for additional information on how your personal and medical information is
protected.

Discomforts associated with the blood draw may include brief pain, slight bleeding, or a bruise
from the site. Rarely, a small blood clot or infection could originate from the site of the needle
puncture. In the event of any physical injury resulting from research procedures, medical
treatment will be provided without cost to you. If you have an illness or injury during this research
study that is not directly related to your participation, you and/or your insurance will be
responsible for the cost of the medical care of that illness or injury.

There is no compensation for taking part in this research study. This study will pay for the cost of
the blood draw and genetic testing. Any required study-related visits outside of standard of care
for your treatment may be covered under this research. Ask the study staff if you have any
questions about bills, fees or other costs related to this study.

Voluntary Participation and Withdrawing Participation
Your participation in this study is voluntary. You may refuse to participate, or may stop
participation at any time, even after signing this document, without a penalty or loss of benefits to
which you are otherwise entitled now and in the future. Your participation may also be stopped by
the study physician without your consent, if he/she feels that is best for you. If you choose to stop
your participation, the researchers will destroy any remaining blood sample and will stop using or
disclosing information about you. Sometimes, however, it may be necessary for information about
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you to continue to be used or disclosed, even after you have canceled your permission or the
study has ended. An example of this would be to show auditing authorities that the study was
conducted properly.

Volunteer’s Statement
When you sign this form, you are agreeing to take part in this research study. This means that
you have read the consent form, your questions have been answered, and you have decided to
volunteer. Do not sign this consent form unless you have had a chance to ask questions, and
have received satisfactory answers to all of your questions. If you have additional questions about
taking part in this study, would like to withdraw, or have a research-related injury, you may
contact the Avera Institute for Human Genetics at (605) 322-3050. If you have questions about
your rights as a research participant, call the Avera Department of Human Subjects Protection at
(605) 322-4706.

□ Yes, I want to donate any remaining blood sample to the AIHG Specimen Bank. Checking
this box provides my consent to have my stored blood sample to be used for future research,
as well as for access to my Avera electronic medical record, if needed. I understand I may
withdraw this consent at any time by calling AIHG at (605) 322-3050.

□ No, I do not want to donate any remaining blood sample to the AIHG Specimen Bank.

I have read and understand the above information. I understand taking part in this
research study is voluntary. I understand I may quit the study at any time without harming
future medical care or losing any benefits to which you might otherwise be entitled. I have
received the AIHG Protecting Your Rights and Privacy as a Research Participant and
Pharmacogenetic Research Schedule of Participation documents. I will be given a copy of
this signed document by requesting a copy by calling the phone number listed below. By
signing below, I am agreeing to take part in this study.

________________________
Name of Patient (Print)
month, year)

_____________________________
Signature

_________
_____________________________
Person Obtaining
Signature
Consent (Print)

___________________
Date (day,

___________________ Name of
Date (day, month, year)
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Appendix F
Patient Invitation Letter

Dear Avera Care Coordination Patient:
As a patient in the Avera Care Coordination program, you have been
identified as being eligible to participate in a research study for a blood test
that can assist your physician in improving your care through medication
management. The test would be available to you at no cost.
Rather than taking a medication and waiting to see if it works, this test
provides information on how your body will process and use medications, as
well as how the medications you currently take interact with each other.
Recommendations can then be made to your care team as to what
medications may work best for you.
In order to enroll in this study, you will need to do the following:
Read and sign an Informed Consent Document. This document
explains what your participation would include, any risks and benefits,
and other information you may want to consider before participating in
the study.
DO NOT sign this document until you have had an opportunity to
speak to staff about it.
Have your blood drawn at an Avera McKennan or other Avera
facility laboratory. If you meet eligibility criteria and sign the Informed
Consent Document, study staff will deliver a Genotyping Panel
laboratory requisition to an Avera location of your choosing for the blood
draw.
Answer a few questions on your past and present experiences with
medications. This information may help the research staff make
additional correlations between genetics and medication responses.
If you do not receive a letter and information from the Avera Institute for
Human Genetics in the next few days regarding this opportunity and
would like to participate, please call (605) 322-3050 for more
information or to see if you are eligib
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APPENDIX G

December 18, 2015 Matthew Stanley, D.O.
AMG University Psychiatry associates 4400 W. 69th Street
Sioux Falls SD 57108
RE: Our Study #2014.080
Dear Dr. Stanley:
Meeting Date: 12/17/2015
Protocol Title: Title: Pharmacogenetic testing in an outpatient population of patients with
Major Depressive Disorder or Depressive Disorder Not Otherwise Specified with Avera
Medical Group Clinics
This is to inform you the Avera IRB renewed its approval of the above research study. The
renewal is granted for an additional 12 months.
The Effective date of the renewal is 12/17/2015: The approval period will expire on
12/16/2016
Our internal number: 8185
The following items were reviewed:
• Continuing Review Report dated 3-Dec-2015
• Informed Consent dated 23-Jan-2015
All conditions for continued approval during the prior approval period remain in
effect. These include, but are not necessarily limited to the following requirements:
• A stamped copy of the most current Informed Consent Document (as noted
above) is included. No other consent documents should be used. Each subject must
sign the approved ICD prior to initiation of any protocol procedures. The original
signed informed consent document must be placed in each subject’s
medical/research chart. In addition, each subject must be given a copy of the
signed consent document.
•

All protocol amendments and changes to approved research must be submitted to the
IRB and not be implemented until approved by the IRB except where necessary to
eliminate apparent immediate hazards to the study subjects.

Please contact the Avera Dept of Human Subjects Protection (DHSP) at (605) 3224706 if you have any questions about the terms of this approval.
Sincerely yours,

Sandra G. Ellenbolt, CIM, JD
Director, Department of Human Subjects Protection/IRB Chair
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APPENDIX H
Table 33
Allele variation:

CYP 2D6 genotype
Allele
*1
*1/*1
*1/*10
*1/*2
*1/*4
*1/*41
*1/*6
*1/*9
*10
*10/*41
*2
*2/*2
*2/*4
*2/*41
*2/*6
*2/*9
*4/*4
*4/*41
*4/*9
*41
*41/*41
Total

Frequency Percent
2.4
3
14
11.3
3
2.4
28
22.6
8.1
10
13
10.5
.8
1
1
.8
.8
1
1.6
2
3
2.4
6
4.8
9
7.3
7
5.6
.8
1
2
1.6
5
4.0
3
2.4
2
1.6
1.6
2
2
1.6
118
95.2
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Table 34
Allele variation CYP2C9gene
Allele Frequency Percent
*1/*1
70
56.5
*1/*12
1
.8
*1/*2
29
23.4
*1/*23
1
.8
*1/*3
13
10.5
*2/*2
3
2.4
Total
117
94.4
Missing 666
7
5.6
Total
124
100.0
Table 35

Allele variation CYP3A4gene
Allele
*1*1
*1/*1
*1/*1,1/*10, *10/*10
*1/*22
*3/*11
Total
Missing 666
Total

Frequency Percent
1
.8
83.9
104
1

.8

10
1
117
7
124

8.1
.8
94.4
5.6
100.0
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Table 36
Allele variation CYP2C19gene
Allele
Frequency Percent
*1/*1
48
38.7
*1/*17
33
26.6
*1/*2
2
1.6
*1/*2A
15
12.1
*1/*2B
1
.8
*1/*8
1
.8
*17/*17
6
4.8
*2A/*17
7
5.6
*2A/*2A
2
1.6
*2B/*17
2
1.6
Total
117
94.4
Missing 666
5.6
7
Total
124
100.0
Table 37

Allele variation CYP1A2gene
Allele
Frequency Percent
*1A/*1A
14
11.3
*1A/*1F
41
33.1
*1B/*1B
1
.8
*1B/*1F
1
.8
*1B/*1L
1
.8
*1B/*1P
1
.8
*1f/*1F
1
.8
*1F/*1F
54
43.5
*1F/*1K
1
.8
*1L/*1L
1
.8
1F/*1L
1
.8
Total
117
94.4
666
Missing
7
5.6
Total
124
100.0
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Table 38
Allele variation CYP2B6gene
Allele
Frequency Percent
*1/*1
26.6
33
*1/*11
1
.8
*1/*15
2
1.6
*1/*2
7
5.6
*1/*22
.8
1
*1/*5
16.9
21
*1/*6
29
23.4
*1/*7 or
1
.8
*5/*6
*1/*7, *5/*6
1
.8
*1/*7,*5/*6
2
1.6
*1/*7,*5/*69
1
.8
*1/7, *5/*6
*2/*5
*2/*6
*4/*5
*5/*5
*5/*6
*6/*14
*6/*15
*6/*6
Total
Missing 666
Total

1
1
4
1
1
1
1
1
7
117
7
124

.8
.8
3.2
.8
.8
.8
.8
.8
5.6
94.4
5.6
100.0
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